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Abstract  
Neurodegenerative diseases (NDs) are fatal and incurable conditions characterized by the 
progressive accumulation in specific brain regions of abnormally folded (misfolded) 
proteins, which are considered disease-specific biomarkers (DSB). These misfolded proteins 
are able to spread through neuroanatomical connected regions and to accelerate the 
conformational conversion of native monomers (seeding), thus progressively amplifying 
the pathological process. Primary tauopathies are NDs associated with the accumulation of 
misfolded tau and include Corticobasal degeneration (CBD), Progressive supranuclear palsy 
(PSP), Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) 
and other cases of Frontotemporal dementia (FTD). Alzheimer’s disease (AD) can be 
considered a secondary tauopathy as it is characterized by tau misfolding in addition to 
amyloid-β (Aβ) protein deposition. Synucleinopathies comprise a group of NDs associated 
with the accumulation of misfolded α-synuclein (αS), including Parkinson’s disease (PD) 
and other atypical parkinsonisms known as Multiple system atrophy (MSA) and Dementia 
with Lewy bodies (DLB). Given the overlap between clinical symptoms among NDs and the 
lack of sensitive and specific diagnostic tests, the definite diagnosis of NDs lay on 
neuropathological detection of these misfolded proteins in post-mortem brain tissues. 
However, recent findings have raised the possibility that trace-amount of DSB might 
circulate in peripheral tissues and body fluids of affected individuals, thus constituting 
easily accessible biomarkers. For this reason, in my PhD project we evaluated the ability of 
an extremely sensitive technique, named Real-Time Quaking Induced Conversion (RT-
QuIC), to detect seeding activity of misfolded tau eventually present in peripheral tissues, 
such as olfactory mucosa (OM), and body fluids (urine and cerebrospinal fluid) collected 
from patients with clinical diagnosis of primary (FTDP-17, FTD, PSP, CBD) and secondary 
(AD) tauopathies. RT-QuIC assay was optimized using a recombinant tau protein fragment 
named tauK18 (4R-tau) as substrate, whose aggregation was efficiently triggered (seeded) 
by the addition of minute amount (attograms) of tauK18 pre-formed fibrils (PFFs) 
previously generated in vitro. We demonstrated that tauK18 RT-QuIC assay was able to 
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detect seeding activity of misfolded tau contained in brain samples of neuropathologically 
confirmed cases of FTDP-17, PSP, and AD. Thus, we performed RT-QuIC analysis of (i) OM, 
(ii) CSF and (iii) exosomes extracted from urine samples collected from patients with 
different primary and secondary tauopathies. As a comparison, we included in the analysis 
samples belonging to patients with different synucleinopathies (PD, MSA, and DLB), 
Multiple sclerosis (MS), Non-demented patients (NDP) and healthy controls (HC). Results 
showed that tauK18 RT-QuIC assay was able to detect tau seeding activity in CBD and PSP 
OM samples, but also in some PD, MSA, DLB and MS cases. Similarly, RT-QuIC analysis of 
CSF samples displayed small differences in tau seeding activity between AD and NDP 
cases. On the other hand, RT-QuIC analysis of urinary exosomes revealed that AD, FTD and 
CBD samples triggered tauK18 aggregation with higher efficiency if compared to HC, thus 
potentially discriminating between tauopathies and healthy subjects. We investigated the 
ability of PFFs generated in vitro from other NDs-associated proteins (3R-tau fragment 
named tauK19, αS, Aβ1-40, and  Aβ1-42) to influence tauK18 aggregation (cross-seeding) and 
we found that some conformational variants of αS PFFs were able to cross-seed tauK18 
aggregation, thus representing a potential issue for our assay and possibly explaining 
results obtained with the analysis of OM samples. Moreover, preliminary structural analysis 
showed that final reaction products were characterized by different morphologies when 
seeded by different (i) OM samples or by (ii) PFFs generated in vitro from tauK19, αS, Aβ1-
40, and  Aβ1-42, suggesting that biophysical assessments might help in discriminating 
between different seeding-competent samples. Although further retrospective analysis is 
required to confirm results obtained with our tauK18 RT-QuIC assay, this preliminary study 
might lay the basis for the development of a new diagnostic approach which combines RT-
QuIC and biophysical techniques to detect tau seeding activity in peripheral tissues and 
body fluids of patients with tauopathies and to discriminate between different pathological 
conditions. 
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CHAPTER I 
INTRODUCTION 
1.1. Neurodegenerative diseases as protein misfolding disorders 
Neurodegenerative disorders (NDs) comprise a wide range of incurable and 
debilitating conditions which primarily affect the central nervous system (CNS) and 
sometimes the peripheral nervous system (PNS) [1]. They include Alzheimer’s disease 
(AD)[2], Dementia with Lewy bodies (DLB) [3], Frontotemporal dementia (FTD) [4, 5], 
Parkinson’s disease (PD) [6, 7] and a series of atypical parkinsonisms comprising Multiple 
system atrophy (MSA), Corticobasal degeneration (CBD) and Progressive supranuclear 
palsy (PSP) [8]. Currently, NDs affect almost 50 million people worldwide [9] and this 
number will increase substantially as the world population rapidly ages. Indeed, aging and 
particular genetic polymorphisms are the most important risk factors for these disorders 
[10]. Most of the NDs are sporadic, however, they can be inherited in 10-20% of cases [11].  
Although comprising a wide spectrum of disorders and presenting phenotypic 
heterogeneity [12], they share several clinical, pathological and molecular features [13]. 
Indeed, they are characterized by synaptic impairment and neuronal loss, which 
progressively lead to cognitive impairment (dementia) and movement disability (ataxia) 
[14]. Moreover, these disorders usually arise in late adulthood and show a slowly 
progressive clinical course [15]. Finally, NDs are characterized by neuropathological 
changes that affect specific brain areas and involve the deposition of aggregates made up 
of abnormally folded (misfolded) proteins, whose secondary conformation is enriched in β-
sheet structures. These protein aggregates are disease-specific and, therefore, they are 
considered important biomarkers of the disease [16]. Indeed, neurodegenerative diseases 
are also known as “protein misfolding disorders” [12, 17-19]. Thus, the molecular 
classification of NDs is mainly protein-based by evaluating the presence of protein 
deposits, their distribution in the brain and their correlation to clinical symptoms [20].  
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NDs have a severe impact on patients and their families’ quality of life, with a huge 
economic burden [21]. Diagnosis of dementia is extremely challenging, especially in the 
early stages of the disease, and relies on clinical evaluations and laboratory tests. 
Therefore, its accuracy is not absolute and definite diagnosis can be formulated only at the 
neuropathological level [22]. Moreover, although several efforts have been made to 
develop disease-modifying therapies, none of them efficiently blocked disease progression 
and no cure is currently available for such devastating disorders.  
1.1.1. Classification 
Classification of NDs is quite challenging and is based on clinical and 
neuropathological evaluations [23-25]. In recent years, leading experts in the field of 
neurodegeneration have refined consensus criteria [26] for disease classification and 
highlighted the importance of the identification of these protein aggregates as specific 
“molecular signature” for each disease (Fig.1.1).  
 
 
Figure 1.1 Main abnormally folded proteins found to aggregate in the CNS of patients with 
neurodegenerative diseases. 
Immunoreactive protein deposits found in NDs are associated with the aggregation of misfolded 
proteins, such as tau, β-amyloid (Aβ), PrPSc, α-synuclein and TAR DNA-binding protein 43 (TDP-43). 
 
 
β-amyloid 
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Sc
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α-synuclein 
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Protein deposits found to accumulate in NDs are associated with the aggregation of 
different misfolded proteins, such as tau, β-amyloid (Aβ), PrPSc, α-synuclein and TAR DNA-
binding protein 43 (TDP-43). Thus, current NDs classification is based on the combination 
of the molecular characterization of the conformationally altered proteins, anatomical 
regions and cell types affected, clinical presentation (symptoms, motor signs) and etiology 
if known (e.g. gene mutations) [12]. Based on the abnormally folded proteins found to 
aggregate in CNS [20], neurodegenerative diseases can be classified as follows 
(summarized in Table 1.1): 
 Tauopathies: heterogeneous group of conditions characterized by intracellular 
deposition of abnormally folded forms of the microtubule-associated protein tau 
(MAPT), accumulating in neurofibrillary tangles (NFTs) mainly in its 
hyperphosphorylated form [27]; tau is important for the assembly and stabilization 
of neuronal microtubules and can also interact with other cellular components 
participating in many neuronal physiological processes [28]. Depending on the 
nature of tau pathology, they can be further divided into primary or secondary: 
 Primary tauopathies: group of diseases where tau is thought to be the 
major player of the pathological processes and include Pick’s disease (PiD), 
Progressive supranuclear palsy (PSP) [4] Corticobasal degeneration (CBD) [5], 
Argyrophilic grain disease (AGD), Globular glial tauopathy (GGT) [29], 
behavioral-variant FTD (bvFTD) [30] and Primary progressive aphasia (PPA) 
[31]. Mutations in the tau MAPT gene can cause a hereditary primary 
tauopathy known as Frontotemporal dementia and parkinsonism linked to 
chromosome 17 (FTDP-17) [32]. 
 Secondary tauopathies: diseases in which tau pathology is considered as 
having another driving force or is combined with other molecular alterations 
[29]. For instance, Alzheimer’s disease (AD) can be considered a secondary 
tauopathy since it is characterized by the accumulation of amyloid-β (Aβ) 
protein (in the form of amyloid plaques) in addition to misfolded tau [27]. 
Another example of secondary tauopathy is represented by the Chronic 
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traumatic encephalopathy (CTE), in which tau pathology is thought to be 
induced by repeated mild head injuries [33]. 
 Synucleinopathies: conditions characterized by intracellular deposition of 
abnormally folded α-synuclein, a protein shown to be localized at presynaptic 
terminal of neuronal axons and to bind membranes [34], but whose physiological 
function has still not been completely understood. Aggregates of α-synuclein are 
found in different pathologies, including Parkinson’s disease (PD), Dementia with 
Lewy bodies (DLB), Multiple system atrophy (MSA) [35] and Pure autonomic failure 
(PAF) [36]. 
 TDP-43 proteinopathies: diseases that show intra-nuclear deposition of TAR 
DNA-binding protein 43 (TDP-43), a member of the heterogeneous nuclear 
ribonucleoproteins (hnRNPs) family able to bind both mRNA and DNA, thereby 
regulating mRNA splicing, stability, and translation as well as gene transcription 
[37]. Hyperphosphorylated, ubiquitinated and cleaved forms of TDP-43 are found in 
the majority of cases of Frontotemporal dementia (FTLD-TDP) [38] and in 
Amyotrophic lateral sclerosis (ALS/MND-TDP) [37].  
 Prion diseases: diseases characterized by the presence of aggregates of the 
misfolded form of the cellular prion protein (PrPC), called scrapie prion protein 
(PrPSc) or prion [39, 40]. The most common form of human prion diseases is the 
Creutzfeldt–Jakob disease (CJD), followed by sporadic Familial insomnia (sFI) and 
Variably protease-sensitive prionopathy (VPSPr). Prion diseases occurs also in 
animals. For instance, scrapie affects sheep, goats, and mouflons, Bovine 
Spongiform Encephalopathy (BSE) occurs in cattle, Chronic Wasting Disease (CWD) 
in cervids and Transmissible Mink Encephalopathy (TME) in mink [41]. 
 FUS/FET proteinopathies: conditions characterized by intra-nuclear and intra-
cytoplasmatic deposition of RNA-binding proteins belonging to the FET 
(FUS/TLS, EWS or TAF15) family. Fused in sarcoma (FUS) is the most represented 
FET member and is a DNA/RNA binding protein that regulates various aspects of 
RNA metabolism, including splicing, mRNA processing and microRNA (miRNA) 
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biogenesis [42], showing several similarities with TDP-43 [38]. FUS pathology 
characterizes familial ALS cases (ALS/MND-FUS) and a rare group of FTLD (FTLD-
FUS), known as Basophilic inclusion body disease (BIBD), atypical FTLD-U (aFTLD-U) 
and Neuronal intermediate filament inclusion disease (NIFID) [43, 44]. 
 Trinucleotide repeat expansion disorder: conditions characterized by 
pathological expansion of unstable trinucleotide repeats in certain genes or introns 
exceeding the normal stable threshold and promoting the aggregation of their gene 
products, such as huntingtin, fragile X mental retardation protein (FMRP) and 
frataxin [45]; repeats expansion in non-coding sequences are responsible for the 
development of Fragile X syndrome (FXS), Friedreich ataxia (FRDA), Spinocerebellar 
ataxia type 8 (SCA8) and type 12  (SCA12), and Myotonic dystrophy (DM); exonic 
(CAG)n repeats expansions that code for polyglutamine (poly-Q) tracts give rise to a 
group of diseases named polyglutamine diseases and comprises Hungtington’s 
disease (HD), Spinal and bulbar muscular atrophy (SBMA), the majority of 
Spinocerebellar ataxia (SCA) cases and few other rare conditions [45]. 
 Neuroserpinopathies: Serpinopathies result from point mutations in members of 
the serpin superfamily, a group of serine protease inhibitors. In the brain, they are 
characterized by the presence of inclusion bodies composed of neuroserpin (α1-
antitrypsin), which have a central role in many biological pathways, such as 
inflammation, complement system, coagulation, fibrinolytic cascade and chromatin 
[46]. The accumulation of neuroserpin was found to cause an autosomal-dominant 
form of dementia named Familial encephalopathy with neuroserpin inclusion bodies 
(FENIB) [47]. 
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Table 1.1 Summary of the most relevant neurodegenerative diseases with their classification based on 
the peculiar aggregated proteins found to accumulate in those conditions. 
 
 
 
 
 
Classification Protein Disease Type 
Primary 
Tauopathies 
Tau 
Pick's disease (PiD) 
Corticobasal degeneration (CBD) 
Progressive supranuclear palsy (PSP) 
Frontotemporal lobar degeneration (FTLD-tau) 
NFT-dementia/PART 
Frontotemporal dementia and parkinsonisms linked to 
chromosome 17 (FTDP-17) 
Secondary Tauopathies 
Tau, Aβ Alzheimer's disease (AD) 
Tau Chronic traumatic encephalopathy (CTE) 
TDP-43 
proteinopathies 
TDP-43 
Frontotemporal lobar degeneration (FTLD-TDP) 
Amyotrophic lateral sclerosis (ALS/MND-TDP) 
FTLD/MND-TDP 
FUS/FET-proteinopathies FUS/FET 
Frontotemporal lobar degeneration (FTLD-FUS) 
Amyotrophic lateral sclerosis (ALS/MND-FUS) 
Synucleinopathies αS 
Parkinson's disease (PD) 
Dementia with Lewy bodies (DLB) 
Multiple system atrophy (MSA) 
Prion diseases PrP 
Sporadic Creutzfeldt-Jakob disease (sCJD) 
Genetic Creutzfeldt-Jakob disease (gCJD) 
Iatrogenic Creutzfeldt-Jakob disease (iCJD) 
Variant Creutzfeldt-Jakob disease (vCJD) 
Kuru 
Variably protease-sensitive prionopathy (VPSPr) 
Gerstmann-Sträussler-Scheinker disease (GSS) 
Fatal familial insomnia (FFI) 
Trinucleotide repeat 
expansion disorders (TRD) 
Htt Huntington’s disease (HD) 
Ataxin,  Spinocerebellar ataxia (SCA) 
FMRP Fragile X syndrome (FXS) 
ARP Spinal and bulbar muscular atrophy (SBMA) 
Neuroserpinopathy Neuroserpin 
Familial encephalopathy with neuroserpin  
inclusion bodies (FENIB) 
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1.1.2. Aggregation of misfolded proteins  
The correct conformation of a protein is usually fundamental for its biologically 
functions. Protein structure depends on its amino acid sequence and local, low-energy 
chemical bonds between atoms in both the polypeptide backbone and in amino acid side 
chains [48]. It is possible to recognize four levels of protein structure by the degree of 
complexity in the polypeptide chain conformation:  
 primary structure is the conformation driven by the amino acid sequence of 
the protein; 
 secondary structure depends on local interactions between stretches of a 
polypeptide chain which can acquire α-helix and β-sheet structures (Fig. 1.2); 
 tertiary structure is the overall three-dimension folding driven largely by 
interactions between side chains; 
 quaternary structure is the orientation and arrangement of subunits in a 
multi-subunit protein. 
 
Figure 1.2  Secondary structure of proteins showing α-helix and β-sheets conformations.   
Protein secondary structure, showing that α-helix is formed when polypeptide chains twist into a 
spiral, whereas in β-sheets polypeptide chains run alongside each other. Both structures are 
mainly driven by the formation of hydrogen bonds between amino acids. 
 
Some of the key proteins that cause neurodegeneration, such as tau, α-synuclein, and Aβ, 
have been shown to contain intrinsically disordered regions (IDRs), as they lack stable 
tertiary and/or secondary structure under physiological conditions, presumably to interact 
with a broad range of binding partners [49]. The flexibility of IDRs is thought to be 
α-helix β-sheets 
H-bonds 
H-bonds 
H-bonds 
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important for the conformational rearrangements which drive the formation of amyloid 
structures [50]. Normally folded proteins are generally characterized by higher content of 
-helix structures (Fig. 2) [51]. Misfolded proteins show a prevalence of -sheet structures 
(Fig. 1.2) and are usually either degraded by the ubiquitin-proteasome system (UPS) or 
refolded correctly by chaperone proteins [52]. However, sometimes these systems fail and, 
as a consequence, misfolded proteins start to aggregate and form oligomers. Oligomers 
are a heterogeneous group of species ranging from dimers to larger protofibrillar 
structures, likely composed of hundreds of monomers (Fig. 1.3) [53]. Oligomers and 
protofibrils are then packaged into longer amyloid aggregates, ranging from 100–200 
Ångström (Å) in diameter [54]. Once formed, these amyloids are deposited as intra- or 
extra-cellular aggregates into the CNS causing cell death and neurodegeneration. 
Protein misfolding can be due to mutations in protein-encoding genes (causing familial 
forms of NDs) [55] or can be caused by several factors (e.g. proteotoxic stress, cellular 
aging) responsible of sporadic forms of NDs. At present, the exact molecular mechanism 
which leads to protein misfolding and aggregation remains still elusive [49]. 
 
Figure 1.3 Proposed mechanism for amyloid formation.  
A misfolded protein that escapes protein control systems might undergo the aggregation pathway, 
involving the formation of oligomers and large aggregates through the elongation of the fibrils, finally 
sequestering other proteins or cellular factors. (Adapted from [53]) 
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It was originally thought that amyloids in the form of large fibrils and aggregates were 
neurotoxic, however now it is widely accepted that oligomers are the most neurotoxic 
species and fibrils formation may actually be a way for the cell to minimize their 
deleterious effects [54]. Indeed, toxicity of oligomers may arise from the abnormal 
exposition of hydrophobic groups on their surface [56], resulting in inappropriate 
interactions with many functional cellular components like membranes and organelles [57]. 
Intracellular aggregates might damage cell integrity, segregate essential factors for cell 
viability, bind to organelles deregulating their function and might disrupt cell membranes, 
resulting in depolarization and alteration of ion homeostasis [58]. Extracellular oligomers 
might interact with cellular receptors and activate undesirable signal transduction 
pathways leading to apoptosis or might interfere with the cellular and tissue network [16]. 
Finally, they could induce cellular oxidative stress by producing free radical species, 
resulting in protein and lipid oxidation and mitochondrial dysfunctions [59]. Thus, neurons 
containing protein aggregates show transcriptional alteration, mitochondrial dysfunction, 
and an impaired protein/RNA quality control system that might critically contribute to the 
initiation and progression of neurodegeneration [60]. 
1.1.3. Propagation and transmission of misfolded proteins 
 Since NDs are characterized by the presence of many protein aggregates, it is 
of fundamental importance to understand the mechanisms through which they are 
generated and how they accumulate in different cells. One of the most puzzling aspects of 
misfolded protein is their ability to interact with their physiological counterparts and force 
them to adopt similar structural alterations (Fig. 1.4) [16]. This phenomenon was initially 
observed in prion diseases, where PrPSc was found to propagate the disease by acting as 
seed for the conformational conversion of the normal protein PrPC to the pathological 
isoform. By seeding misfolding of the PrPC into PrPSc, prions spread in the CNS (and 
sometimes to the periphery) and can be transmitted (more or less efficiently) between 
individuals of the same or different species. Similarly, recent findings showed that tau, α-
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synuclein, and Aβ can also transmit their abnormal conformation to their normally folded 
isoforms [16]. 
 
 
Figure 1.4 Proposed model for protein misfolding propagation.  
A misfolded protein is able to interact with its physiological counterpart (native protein) and force it to 
adopt similar abnormal conformations, leading to the progression of the misfolding process. 
 
This process seems to sustain the pathological process associated with many NDs 
and can be reproduced in vitro [61].  In the seeding-nucleation model of protein 
misfolding propagation (Fig. 1.5A), a  slow  and  thermodynamically  unfavorable  
nucleation  phase (lag phase) induce the  formation  of  a  stable  nucleus  of  polymerized  
protein, called seed, followed  by  a  rapid  elongation stage in which seeds rapidly  grow  
by  incorporating monomeric proteins into the polymer (elongation phase) [61]. The 
kinetics of protein aggregation may be graphically represented by plotting amyloid 
formation against time, showing a sigmoidal curve characterized by a slow lag phase and a 
rapid elongation phase as depicted in Fig. 1.5A (blue line).  
A typical feature of the seeding–nucleation model is the ability of pre-formed fibrils 
(PFFs) to greatly accelerate the aggregation process by recruiting the soluble normal 
protein into the growing aggregate [62]. Thus, the aggregation kinetics of the protein is 
efficiently accelerated by the addition of pre-formed seeds, showing a reduction in lag 
phase as in Fig. 1.5A (red line). This process seems to occur in vivo and drives disease 
progression along routes of neuronal connectivity on the basis of trans-cellular 
propagation of protein seeds [63].  
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It is fundamental that misfolded proteins interact with their physiological 
counterparts. Therefore, they need to spread from cell to cell by mechanisms that are still 
not well understood (Fig. 1.5B). Different hypotheses have been postulated so far. For 
instance, cellular endocytic mechanisms can be involved in the release and uptake of 
protein aggregates and in their trans-cellular spreading [64]. Aggregates might bind to 
heparan sulfate proteoglycans (HSPGs) on the cell surface and trigger the formation of 
large endocytic vesicles (macropinosomes) that bring aggregates into cells [65]. Receptor-
mediated endocytosis may also occur through the binding of aggregates to specific 
proteins at the cell surface [66]. Moreover, a growing body of evidence proposes that 
exosomes play important roles in the cell-to-cell transmission of pathogenic protein 
aggregates, thereby contributing to the pathological and clinical progression of NDs  [67]. 
 
 
 
Figure 1.5 Kinetic principle of protein aggregation and inter-cellular aggregates transmission.  
A) Simplified scheme illustrating the kinetics of protein fibrillation (blue line) and seeded polymerization 
(red line). The addition of pre-formed fibrils (PFFs) as ‘seeds’ drastically reduced the lag phase and 
accelerate protein aggregation (red line). B) Illustration of the seeded polymerization principle in cell-to-
cell aggregates transmission. When protein aggregates are transferred from one cell to another, the 
transferred aggregates could act as ‘seeds’ in the recipient cells. (Adapted from [66])  
 
A B 
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Protein misfolding can occur between cells of the same organism but, in some cases 
and with low efficiency, can occur between different organisms, thus highlighting the 
pathological features of such misfolded proteins [62].  
This feature has been extensively described for prion diseases, which can be easily 
transmitted within hosts belonging to the same species while the efficiency of this 
transmission is almost abolished between hosts belonging to different species. This is due 
to the so-called species barrier, where differences in the aminoacidic sequence of the host 
vs donor proteins drastically reduced the ability of the misfolded protein (PrPSc) to drive 
the conformational conversion of PrPC [40].  
However, in particular conditions (e.g. high sequence homology, intrinsically 
unfolding and high flexibility of proteins) the species barrier might be over-crossed 
allowing protein misfolding transmission between different species [68]. Indeed, natural 
transmission of prion diseases, such as the BSE epidemic in Great Britain in the 1980s in 
cattle which cause the variant Creautzfeldt-Jakob Disease (vCJD) in humans due to cattle 
food consumption, have raised important health questions. Thus, the potential intra- and 
inter-species transmissibility of other misfolded proteins (Aβ, tau, and α-synuclein) is under 
investigation [69].  
The self-propagation ability of misfolded Aβ was proposed decades ago from in 
vitro studies [61] and from inoculation experiments with non-human primates [70]. 
Recently, it has been shown that the intracerebral injection of Aβ amyloid-rich brain 
extracts from Alzheimer’s disease (AD) patients accelerate the formation of Aβ plaques in 
genetically modified mouse models of AD pathology, showing that Aβ can be induced to 
deposit in vivo through a prion-like mechanism [71] 
In vitro tau preformed fibrils (PFFs) can act as seeds in a templated fibrillization 
reaction in which misfolded tau recruits and corrupts normal, soluble tau into a fibrillar 
conformation. This process has been demonstrated in vitro and in vivo with recombinant 
tau proteins assembled into PFFs under different conditions and shown to propagate 
misfolded conformations that are capable of further seeding tau fibrillization in cell-culture 
models and tau transgenic mice [72, 73]. 
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Similarly, the intracerebral injection of tauopathy brain extracts induced tau 
deposition in transgenic [74, 75] and wild-type mice [76]. When young transgenic mice 
expressing tau with the human pathological mutation P301S were inoculated with old mice 
brain extracts containing tau aggregates, they showed tau assembly into filaments and its 
spreading to distant brain regions [74]. Propagation of tau pathology from the injection 
site to connected areas suggested the potential neuronal uptake and transport of tau 
aggregates. Lee and colleagues showed that intracerebral inoculation of tau fibrils purified 
from AD brains resulted in the formation of abundant tau inclusions in wild-type mice, 
both in the site of injection and anatomically connected brain regions [72]. Interestingly, 
brain extracts from various human tauopathies, such as AD, TD, PiD, AGD, PSP, and CBD, 
have induced different tau lesions in wild-type mice who resemble those in the relative 
human diseases [77]. 
The same mechanism has been proposed for α-synuclein propagation, as the 
intracerebral injection of brain extracts containing pathological α-synuclein into transgenic 
mice stimulated the formation of α-synuclein lesions [78, 79]. The progression of α-
synuclein pathology along neuronal routes leads to progressive neurodegeneration and 
signs of motor dysfunction resembling those found in Parkinson’s disease (PD) [79]. 
Surprisingly, αS displayed prion-like characteristics when PD patients received fetal nigral 
dopaminergic nerve cells grafts into the brain as part of a clinical trial. Investigation at 
autopsy revealed the presence of αS deposits in the transplanted cells suggesting that 
transmission occurred from the host to the grafted tissue in the 11–16 years post‐surgery. 
Moreover, intracerebral injections of in vitro α-synuclein PFFs or autopsy-derived brain 
extracts from patients affected by Dementia with Lewy bodies (DLB) induced the formation 
of Lewy bodies composed of aggregated α-synuclein and neuronal loss in wild-type mice 
[79]. Interestingly, some α-synuclein PFFs were able to induce tauopathy [80], possibly due 
to α-synuclein acting as seed for tau aggregation. This phenomenon is known as cross-
seeding or heterologous seeding (Fig. 1.6) and involves the ability of pre-formed seeds 
from one protein (e.g. αS) to greatly accelerate the aggregation process of other proteins 
(e.g. tau).  
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Several in vitro and in vivo studies suggested that misfolded proteins associated with 
different NDs can promote their mutual aggregation, potentiating pathological 
mechanisms and accelerating disease progression [81]. In vitro interaction between Aβ and 
αS has been reported [82], as well as the binding between Aβ and tau forming soluble 
complexes that promote the aggregation of both proteins [83]. 
 
Figure 1.6. The heterologous seeding phenomenon, also known as cross-seeding.  
Homologous seeding occurs when preformed seeds (light blue squares) are able to facilitate 
and speed up the polymerization process of the same monomeric protein (light blue square). In 
the heterologous seeding, seeds composed of one misfolded protein can promote the 
polymerization of a different protein. 
 
Transgenic mice developing both Aβ, α-synuclein and tau deposits displayed an 
accelerated cognitive decline which positively correlates with the deposition of all three 
amyloidogenic proteins [84]. Moreover, neuropathological studies confirmed the presence 
of αS aggregates in approximately 50% of the AD patients and its deposition was 
associated with more severe pathological outcomes [85]. 
As reported in this chapter, several studies give strong support for conformationally 
altered proteins as the agent driving the transmission and propagation of 
neurodegeneration in protein misfolding diseases and support the concept that these 
misfolded proteins may propagate as prions. 
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1.1.4. Conformational variants of misfolded proteins 
We have previously described that protein aggregates can be efficiently propagated 
in cell culture and animal models. There is now increasing evidence that distinct 
conformational variants of the same protein, also known as strains, might account for 
different neurodegenerative diseases (or even distinct phenotypes of the same pathology) 
and might propagate their aberrant conformations in a templated-assisted mechanism 
(Fig. 1.7). 
Indeed, it has been shown that tau aggregates propagate distinct strains in cell 
culture and induce different pathological patterns in mice [86]. The tau inclusions-
containing cell lysates were able to induce the same inclusion pattern into new cells, 
suggesting a process of templated conformational conversion for tau strikingly similar to 
that characterized for prion strains [87]. Moreover, these clones displayed distinct 
biochemical features, seeding activity and toxicity in vitro. Similarly, after injecting these 
lysates into the hippocampus of transgenic mice (P301S), some lysates induced inclusions 
in vivo that were morphologically and biochemically similar to what produced in cells, 
supporting the idea that distinct strains of misfolded tau might be propagated and could 
produce distinct pathologies. They also demonstrated that brain homogenates from a 
range of tauopathies, including AD, AgD, CBD, PiD and PSP would give rise to distinct 
patterns of tau deposition and different pathologies in tau cell culture model [86].  
Interestingly, the intracerebral injection of brain homogenates from humans with 
pathologically confirmed cases of AD, TD, PiD, AgD, PSP, and CBD led to the formation of 
neuronal and glial tau inclusions in transgenic mice expressing human tau, producing tau 
lesions similar to those of the human disorders [77]. Indeed, injection of PSP brain 
homogenate gave rise to silver-positive neuronal and glial tau aggregates similar to tufted 
astrocytes, the hallmark lesion of PSP. The injection of CBD homogenates produced 
neuronal inclusions and silver-positive structures reminiscent of astrocytic plaques. After 
AGD brain homogenates inoculation, argyrophilic grains and silver-negative astrocytic tau 
inclusions were present [77]. Similar inclusions, but fewer in number, were induced after 
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the intracerebral injection of brain homogenates from human tauopathies into non-
transgenic mice [88, 89]. 
The presence of different Aβ strains have been also suggested by the finding that 
different genetic cases of AD are associated to different clinical phenotypes, distinct  Aβ 
deposition pattern and unique biochemical profiles of Aβ species [90]. Interestingly, 
transgenic AD mouse models inoculated with human brain from patients affected by 
distinct AD phenotypes generate distinct profiles of pathological Aβ species that reflect the 
human condition and these strain‐specific features were conserved following serial 
passage in mice [90]. Consistent with these observations, different recombinant Aβ fibrils 
were produced by in vitro fibrillization in the absence or in the presence of detergent that 
induced differential plaque characteristics and Aβ peptide ratios in mouse brain [91]. 
Hence, the conformation of the Aβ species appears to be a contributing factor to the 
clinical and pathological heterogeneity of the disease.  
Similarly, recombinant αS monomers can assemble into in vitro PFFs with distinct 
conformations and biological activities [80]. Indeed, through repetitive seeded fibrillization 
in vitro, Guo and colleagues were able to generate two different conformational variants of 
αS (strain A and B). Strain B was found to be less potent in seeding αS aggregation than 
strain A, however, efficiently induced the aggregation of tau in both primary neurons and 
transgenic mice. This finding not only demonstrates the possibility to generate αS strains 
in vitro but also illustrates that some conformational variants of αS are able to influence 
the aggregation propensity of tau in vivo (cross-seeding). Morphological differences in αS 
deposits have been also observed in distinct human synucleinopathies. Differential 
proteinase-K cleavage of α-synuclein aggregates was observed in the brains of PD 
patients, indicative of alternative α-synuclein conformations [80].  
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Figure 7. Conformational strains and their implications for the spectrum of NDs.  
Conformational variants of the same misfolded proteins (strains) may account for the large heterogeneity 
of NDs and may provide a molecular explanation for distinct diseases associated with the deposition of 
the same misfolded protein, such as (A) PrPSc in prion diseases and (B) misfolded α-synuclein (mis αS)  in 
synucleinopathies. 
 
Insoluble αS fraction extracted from the brain of a patient with Dementia with Lewy 
bodies (DLB) was able to induce αS aggregation in wild type mice [92], which resemble LBs 
pathology. In a particular form of Parkinson’s disease (PD), named PD with dementia (PDD), 
Lewy bodies (LBs) in the substantia nigra showed biochemical dissimilarities from LBs in 
neocortical areas of these patients, therefore different abnormal conformations may be 
also acquired among the same condition. Interestingly, MSA patients but not PD or DLB 
patients induced αS aggregation in a mouse model expressing A53T mutant αS [93, 94]. 
These results suggest that potential conformational differences between pathological αS 
might drive the diversity of clinical manifestations observed in synucleinopathies. 
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1.1.5. Misfolded proteins structural polymorphisms 
Due to the low solubility nature of amyloid species, few structures were determined 
at high resolution. However, recent advances in solid-state Nuclear Magnetic Resonance 
(NMR) and in cryo Electron Microscopy (cryo-EM) have generated substantial advances in 
atomic-level structural information of physiologically relevant amyloid proteins including 
yeast prions [95], α-synuclein [96], Aβ [97] and tau [98] [99], the latter extracted from post 
mortem human brain tissue (Fig. 1.8).  
These structures have elucidated that different protein strains are associated with 
different diseases, as it has been described for tau, whose cores in paired helical (PHFs) and 
straight filaments (SFs) in AD were found to be significantly different from those found in 
Pick’s disease [100].  
 
Figure 1.8 Cross-β structure and tau deposits in Alzheimer’s disease brain.  
From left to right, the upper panels show a schematic of the β-strand arrangement in the cross-β core of 
an amyloid fibril; the AD brain used for cryo-EM; and a Thioflavin-S stained light microscopy image 
showing abundant neurofibrillary tangles in temporal cortex. Lower panels, an electron micrograph of 
negatively stained filaments with a blue arrow indicating a paired helical filament (PHF) and a green 
arrow indicating a straight filament (SF); cryo-EM reconstructions of PHFs (blue) and SFs (green) with 
detailed cross-sections; and de novo atomic models of filaments showing C-shaped subunits stacked to 
form each protofilament, with protofilaments paired into twisted polymorphic fibrils (adapted from [99]) 
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Based on these observations, two all-β structural motifs have been proposed to be 
associated with amyloid and prion structure: cross-β packing and β-helices or solenoid 
[101]. The generic cross-β structure is a polypeptide scaffold characterized by arrays of 
continuous β-sheets, separated by an inter-sheet distance of 8–12 Å running parallel to the 
long axis of the fibrils (Fig. 1.9A). The importance of sequence-independent hydrogen 
bonding in defining the cross-β fold is highlighted by the observation that polar, non-polar 
and even homopolymeric sequences of amino acids can form cross-β amyloid fibrils [102], 
making this structure widely accessible to peptides and proteins of varying lengths with 
unrelated amino acid sequence similarity. On the other hand, β-solenoids (Fig. 1.9B) are 
intricate structures composed of three β-sheets arranged in a triangular fashion, mediated 
by specific interactions that are not accessible to most amino acid sequences [103]. 
Moreover, the promiscuity of the cross-β fold allows this structural scaffold to template 
dissimilar protein molecules and cross-seed the aggregation of proteins with at least 70% 
of sequence homology [104].  
Atomical evaluation of tau protofilament extracted from human AD brain displayed 
the presence of both sidechain-specific β-helical and generic cross-β structural elements 
(Fig. 1.9C). The core of the paired helical filaments and straight filaments are composed of 
eight β-sheets along the length of the protofilament, adopting a C-shaped architecture. 
Each C consists of a β-helix region with three β-sheets are arranged in a triangular fashion, 
and two regions with a cross-β architecture characterized by pairs of β-sheets that pack 
anti-parallel to each other. Significant differences in the lateral contacts formed between 
two C-shaped fold structures might give rise to the ultrastructural polymorphism [105] 
displayed by tau paired helical filaments and straight filaments in AD. Moreover, the 
different fold of tau filaments in human Pick’s disease and AD brains, despite having many 
β-structure residues in common [100], can be explained by the discovery that tau residues 
337–357 can adopt both a canonical β-helix structure in AD and cross-β packing in Pick’s 
disease. This finding highlights the importance of molecular polymorphism [106] in 
generating disease-specific conformations of tau filaments.  
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Figure 1.9 Atomic structures of amyloid fibrils, viewed down the fibril axis, showing the cross-β structure, 
β-helices and a combination of cross-β and β-helical structural motifs. 
A) The cross-β packing between laminated β-sheets is generic and can be formed by any amino acid 
sequence (open circles). Backbones of cross-β structures from AD, PiD and another amyloidogenic 
fragment (TTR105-115) showed a high level of overlay. B) β-helices require a specific pattern of 
hydrophobic residues (green-filled circles), polar residues (blue-filled circles) and a glycine (pink-filled 
circle) closing the triangular motif. Overlay of the backbones of the β-helix in AD tau filaments and in the 
[HET-s] prion. C) Schematic view of the C-shaped protofilament core formed by the tau protein in 
human Alzheimer’s disease brain. Each C-shaped protofilament consists of a β-helix region, where three 
β-sheets are arranged in a triangular fashion, and two regions with a cross-β architecture, where pairs of 
β-sheets pack anti-parallel to each other (Adapted from [99]). 
 
Different amyloid fibril polymorphisms have been shown to possess distinct biophysical 
properties, such as surface hydrophobicity [98], fibrillization kinetics [107], thermodynamic 
stability [108] and in vivo pathogenicity [109]. Thus, the sequential, structural and physical 
determinants of fibril polymorphisms might lead to a variety of behaviors in vivo, possibly 
resulting in a broad spectrum of disease phenotypes. 
 
 
 
 
 
 
A B C 
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1.2. Tauopathies 
Human tau is encoded by the microtubule-associated protein tau gene (MAPT), a 
long and unique gene (134 kb) containing 16 exons located on chromosome 17 in position 
17q21 [110].  Its sequence is well conserved among mammals, with some regions 
characterized by high sequence homology (97 to 100 %) [111], especially those located in 
the microtubule-binding domain.  
In humans, tau is expressed mainly in neurons, where it localizes to axons [112] 
promoting axonal transport and neuronal integrity [113] and, to a lesser extent, to 
dendrites, where interacts with factors able to modulate post-synaptic receptor activity 
[114]. However, tau protein can be also found in other cell types, such as glial cells [115, 
116]. Moreover, tau mRNA and protein are present in several peripheral tissues, such as 
heart, kidney, lung, muscle, pancreas, testis, as well as fibroblasts [117].  
Tau expression is developmentally regulated by alternative splicing of exons 2, 3 
and 10, producing six different isoforms in the human adult brain (Fig. 1.10) accordingly to 
the variable number of N-terminal insertions (0,1 or 2) and C-terminal repeated regions (3 
or 4), ranging from 352 to 441 amino acids [118]. Exon 2 (E2) and 3 (E3) encode for 
insertions located at the N-terminal which might be totally excluded (0N isoforms), 
partially retained (1N) or completely translated (2N). Exons 9-12 (E9-12) encode 31/32-
aminoacids imperfect repeats which, together with flanking regions, compose the 
microtubules (MTs)-binding domain [119]. Alternative splicing of exon 10 (E10) gives rise 
to tau isoforms with three (3R) or four (4R) MTs-binding repeats, found in equal amounts 
in the normal adult human brain [120]. Interestingly, in fetal rodent and human brain, E2, 
E3, and E10 are excluded and a single isoform is produced (0N3R), whereas in adult rodent 
brain only the three E10+ single isoforms are expressed producing only 4R tau isoforms 
[121]. Differences in tau isoforms ability to bind MTs have been observed, with 4R tau 
being able to bind MTs three-fold more strongly and assembling MTs more efficiently than 
3R tau [122].  
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Figure 1.10 Alternative splicing variant isoforms of tau.  
The six different isoforms of tau generated by alternative splicing of exons 2 and 3 for the N-terminal 
region, which encode the N1 and N2 segments of the protein (labeled here in orange and red, 
respectively), and of exon 10 in the microtubule-binding region, which encodes the second repeat 
sequence (R2, shown in green). The microtubule-binding domain is composed of 3 or 4 repeat 
sequences (blue and green). These domains form the core of tau fibrils, and when expressed 
recombinantly as truncated protein products, they are referred to as 3R and 4R or alternatively as K19 
and K18, respectively. (From McHugh, K.P., Morozova, O.A., & Colby, D.W. (2015). Tau strains and their 
propagation in experimental disease models. Book: The Prion Phenomena in Neurodegenerative 
Diseases. Edited by Nova Science Publishers, Inc ISBN: 978-1-63483-399-8) 
 
Tau binding to MTs through its MTs-binding domain increases the rate of 
polymerization, decreases the rate of transit into the shrinking phase (catastrophe) and 
inhibits the rate of depolymerization of MTs [123]. Biophysical studies have revealed the 
natively unfolded nature of tau, which maintains a highly flexible conformation and overall 
has a low content of secondary structures [124]. The N-terminal part is referred to as the 
projection domain since it projects from the microtubule surface where it may interact with 
other cytoskeletal elements, with the plasma and organelles membranes or with proteins 
involved in signal transduction pathways, such as PLC-γ and Src-kinases [125]. The C-
terminal part is also able to participate in other cellular functions and to regulate tau 
phosphorylation state through its binding to protein phosphatase 2A (PP2A) [126] or 
presenilin 1 (PS1) [127].  
In order to study tau aggregation process in vitro, recombinant tau purified from E. 
Coli was generated, however, it shows very little intrinsic tendency to aggregate 
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presumably due to the lack of a series of post-translational modifications required for its 
aggregation [128]. Indeed, truncated tau constructs that include the 3R and 4R domain 
alone, named K19 and K18 respectively (Fig. 9), aggregates much faster than full-length tau 
in in vitro fibrillation studies. Thus, they are often used to study tau aggregation in vitro 
and to represent aggregation properties of the two major classes of tau isoforms [129].  
The developmental expression of different tau isoforms and their differential affinity 
to MTs suggests the presence of particular isoform-associated functions required for tau–
MT interactions in modulating the extent and rate of microtubule assembly and in 
maintaining the dynamic stability of the neuronal cytoskeletal architecture [130]. Since tau 
is the major microtubule-associated protein of a mature neuron [131], its functions are of 
particular importance for the maintenance of fundamental brain functions, such as cellular 
integrity and morphology, axons and dendrites formation and neuronal trafficking and 
signaling [132]. 
There is preferential accumulation of 3R or 4R tau in various tauopathies, thus giving 
the possibility to further classify these pathologies (Table 1.2): in AD, 3R and 4R tau 
accumulate with a 1:1 ratio, 4R tau accumulates preferentially in PSP and CBD, while 3R tau 
accumulates in Pick’s Disease [133]. In FTDP-17, there is often a two- to six-fold increase in 
the 4R/3R ratio. Indeed, cases associated with P301L tau mutation usually display a 
predominant 4R tau isoform deposition. However, such aggregates composition strictly 
depends on the localization and the effect of MAPT mutation. [133]. 
 
Table 1.2 Classification of the most common tauopathies based on the major tau isoforms found to 
accumulate in each condition. 
 
Tau isoform Tauopathy 
3R Pick’s Disease (PiD) 
4R 
Progressive supranuclear palsy (PSP) 
Corticobasal degeneration (CBD) 
Frontotemporal dementia-P301L mutation (FTDP-P301L) 
3R + 4R Alzheimer’s disease (AD) 
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Interestingly, the electrophoretic profile of insoluble tau purified from brain of 
patients with different tauopathies correspond to the specific isoforms that accumulate 
together with their phosphorylation levels, thus it is often disease-specific [134]. As 
described in Fig. 1.11, biochemical characterization of insoluble tau extracted from AD 
brain reveals the presence of three main bands (tau60, 64 and 69), also referred to as PHF-
tau, corresponding to the molecular weight of 3R and 4R isoforms and relative 
phosphorylation levels. Sometimes a 72–74 kDa faint band is also present and corresponds 
to the longest tau isoform.  
 
Figure 1.11 Biochemical profiles of abnormal tau found in different tauopathies.  
Schematic representation of electrophoretic bands pattern and the relative isoforms composition (right 
of each frame). The six tau isoforms are involved in the formation of the typical AD-triplet tau60, 64 and 
69 with the minor tau74 variant. The typical PSP/CBD doublet tau64 and tau69 is related to the 
aggregation of hyperphosphorylated tau isoforms with exon 10. The FTDP-17 families with mutations in 
exon 10 or intron 10 exhibit profiles depending on the associated mutation (middle panel). 
Hyperphosphorylated tau proteins without exon 10 aggregated in PiD are detected as a tau60, 64 
doublets (right panel). 
 
Using AD PHF-tau preparations, Goedert and colleagues showed that 
dephosphorylated PHF-tau proteins have a similar electrophoretic mobility than the six 
recombinant tau isoforms [135]. Thus, it was possible to identify the following scheme (Fig. 
11): tau60 results from the phosphorylation of 0N3R isoform, tau 64 from the 
phosphorylation of 1N3R and 0N4R tau variants and tau69 from the phosphorylation of 
2N3R and 1N4R tau variants. Phosphorylation of the longest tau isoform (2N4R) induces 
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the formation of the additional hyperphosphorylated tau band with molecular weights 
ranging from 68 to 72 kDa according to its degree of phosphorylation. PSP and CBD 
showed distinct biochemical profiles from that of AD (corresponding to the aggregation of 
the 4R isoforms) and that of PiD (corresponding to the aggregation of 3R tau). Indeed, PSP 
and CBD insoluble tau present two main bands corresponding to tau64 and 69, whereas 
PiD tau bands possess a molecular weight (MW) of 60 and 64 kDa. In FTDP-17 immunoblot 
tau bands depend on the class and the effect of the mutation associated with the disease: 
P301L, the most common tau mutation, and others located in the proximity of exon 10 or 
in the intronic region, are associated with the formation of 4R insoluble tau presenting MW 
of 64 and 69 kDa. Other mutations, however, may promote the aggregation of both 
isoforms thus producing insoluble tau with MW of 60, 64 and 69 kDa. (Fig. 1.11) [136]. 
1.2.1. Alzheimer’s disease 
Alzheimer’s disease (AD) is the most frequent cause of dementia [137] and is 
characterized by extracellular deposition of β-amyloid plaques and the intracellular 
accumulation of tau in neurofibrillary tangles (NFTs).  The vast majority of AD occurs from 
an apparently sporadic origin (sAD) and is characterized by a typical late-onset (80–90 
years of age) with an average duration of illness of 8–10 years [138]. sAD seems to be 
driven by a complex interplay between genetic and environmental factors, in which 
genetics accounts for 70% of AD risk [139]. Mutations in three genes, which are amyloid 
precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2), are causative of rare 
familial forms of AD (fAD) characterized by early disease onset (30-50 years of age) [140].  
The typical presentation of AD is centered on episodic memory deficits, starting 
from amnestic mild cognitive impairment (MCI) [141]. Subsequently, difficulties in the 
simultaneous execution of multiple tasks and loss of confidence may emerge, together 
with more profound cognitive impairments as the condition progresses, starting to 
interfere with activities of daily living [142]. In the late stages of the disease, behavioral 
change, impaired mobility, hallucinations, and seizures may also be present, finally leading 
to death [143]. 
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Amyloid plaques are extracellular accumulations composed of abnormally folded Aβ 
with 40 or 42 amino acids (Aβ40 and Aβ42), two products of APP metabolism [144]. Aβ42 is 
more abundant than Aβ40 within plaques due to its higher rate of fibrillization and 
insolubility [145]. Amyloid deposition does not always follow a stereotypical pattern of 
progression but seems to broadly develop in the isocortex and only latterly affects 
subcortical structures. Entorhinal cortex and hippocampal formations are less involved in 
Aβ pathology [146].  
NFTs are mainly composed of paired helical filaments (PHFs) built up by 
hyperphosphorylated tau (Fig. 1.12d) [144]. Tau pathology typically begins in the 
entorhinal cortex and hippocampus before spreading to the isocortex, whereas primary 
sensory, motor, and visual areas are not normally involved [141]. Neuronal and synapse 
loss typically correspond to tangle formation, indeed it has been shown that AD clinical 
features and severity are better correlated with NFT pathology than β‐amyloid deposition 
[146]. Typical changes accompanying NFTs are the neutrophil threads (Fig. 1.12e), which 
are thought to result from the breakdown of dendrites and axons of the tangle-bearing 
neurons [99]. 
Ultrastructural studies on AD brain specimens revealed that NFTs are primarily made 
of paired helical filaments (PHFs) of 3R and 4R tau fibrils (ratio 1:1), which are tau fibrils of 
≈10 nm in diameter that form pairs with a helical tridimensional conformation at a regular 
periodicity of ≈65 nm [144]. A small proportion of fibrils within the NFTs do not form pairs 
but give the appearance of straight filaments (SFs) although sharing the same structural 
core of PHFs [147], as shown in Paragraph 1.1.5.  
Three NFTs morphological stages have been identified: (1) pre-NFTs or diffuse NFTs 
are diffuse tau staining within the cytoplasm of otherwise normal-looking neurons, with 
well-preserved dendrites and a centered nucleus; (2) mature or fibrillar intraneuronal NFTs 
(iNFTs) consist of cytoplasmic filamentous aggregates of tau that displace the nucleus 
toward the periphery of the soma causing distorted-appearing dendrites; (3) extraneuronal 
“ghost” NFTs (eNFTs) result from the death of the tangle-bearing neurons and are 
identifiable by the absence of nucleus and stainable cytoplasm in their proximity [148]. 
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1.2.2. Progressive supranuclear palsy (PSP)  
Progressive supranuclear palsy is an atypical parkinsonism characterized by axial 
rigidity, postural instability, and unexplained falls, with most patients, also developing 
progressive vertical gaze palsy, dysarthria, and dysphagia [149]. Five clinical variants have 
been described: one classical PSP (Richardson's syndrome) and four atypical variants of 
PSP including PSP-Parkinsonism (PSP-P), PSP-Pure akinesia with gait freezing (PSP-PAGF), 
PSP-corticobasal syndrome (PSP-CBS) and PSP-progressive non-fluent aphasia (PSP-PNFA) 
[133]. Richardson's syndrome is the most common clinical variant and manifests with a 
lurching gait, falls due to postural instability, cognitive impairment and slowing of vertical 
saccadic eye movements. Progressively patients may develop other problems such as 
speech deficits, supranuclear gaze palsy, and difficulties in swallowing. PSP-P is 
characterized by prominent early parkinsonism, including tremor, limb bradykinesia, axial 
and limb rigidity [150]. PSP-PAGF shows progressive freezing of gait, speech and writing 
early in the course of the disease, whereas axial rigidity and supranuclear downgaze paresis 
may emerge after a decade. PSP-corticobasal syndrome (PSP-CBS) has asymmetric cortical 
atrophy and can clinically mimic CBD manifestations. PSP-PNFA patients firstly show the 
presence of speech anomalies (apraxia of speech, agrammatism, phonemic errors) and 
motor symptoms appear later in the course of the disease.  
The typical neuroanatomical regions affected in all PSP cases include basal ganglia, 
subthalamic nucleus, and substantia nigra [151]. Pathology of the cerebellar dentate 
nucleus and the cerebellar outflow pathway (dentato-rubro-thalamic pathway) is usually 
severe and associated with profound atrophy of the superior cerebellar peduncle [152]. 
Neuropathological evaluation of PSP brain lesions reveal the presence of 4R tau-associated 
NFTs in neurons and glia of the basal ganglia, diencephalon, brainstem, and spinal cord; 
however, the hallmark lesion is the presence of tuft-shaped astrocyte, which are usually 
abundant in the motor cortex and the corpus striatum [153]. Tufted astrocytes are distinct 
and differ from astrocytic lesions in other neurodegenerative disorders (Fig. 1.12h), such as 
astrocytic plaques that are typically found in Corticobasal degeneration (CBD) [154]. 
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Oligodendroglial lesions are also present in PSP and appear as argyrophilic and tau-
positive globose tangle (Fig. 1.12g), so-called coiled bodies, and they are usually 
accompanied by thread-like processes in the white matter, especially in the diencephalon, 
brainstem and cerebellum [155]. 
From a neuropathological point of view, microscopic changes are similar in the 
different PSP variants, however, the distribution of tau pathology determines the particular 
clinical presentation, as some cases have severe brainstem involvement (e.g., PSP-PAGF) 
and others important cortical involvement (e.g., PSP-CBS and PSP-PNFA) [156]. The basis 
for anatomical selective vulnerability to tau pathology in PSP and its variants remains to be 
determined. 
1.2.3. Corticobasal degeneration (CBD) 
Corticobasal degeneration (CBD) is an atypical parkinsonism which presents a range 
of clinical presentations mainly associated with the region involved by focal cortical 
degeneration [157]. The classic clinical presentation of CBD, which is referred to as the 
corticobasal syndrome (CBS), is associated with asymmetrical rigidity and apraxia, often 
with dystonia and alien limb sign, accompanied by asymmetrical cortical degeneration of 
the superior frontal gyrus and superior parietal lobe [158]. Atypical presentations are 
common, including clinical manifestations similar to behavioral variant-FTD (CBD-bvFTD) 
with focal atrophy in the frontal lobes [159] or to Progressive non-fluent aphasia (CBD-
PNFA) with focal degeneration in perisylvian areas (Fig. 1.12c) [160].  
The characteristic pathological sign in CBD is 4R tau accumulation in cell processes 
of neurons and glia in the cortex, basal ganglia, thalamus and brainstem [161]. Particularly, 
CBD specific histopathological lesion consists of astrocytic plaques, which are not present 
in other disorders [154] and are visible as blurry outgrowths from the astrocyte (Fig. 1.12I) 
[162]. In the affected areas, ballooned neurons (BN) are present as swollen and vacuolated 
cortical neurons [163]. Abnormal tau-positive, thread-like processes are present in both 
gray and white matter of cortical and subcortical regions and are typical CBD 
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neuropathological signs, accompanied by variable, sometimes sparse, oligodendroglial 
inclusions [161]. 
1.2.4. Frontotemporal dementia and parkinsonism (FTDP-17) 
Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) is 
a rare familial disorder with autosomal dominant inheritance [164]. Its three major clinical 
features include behavioral disturbances, cognitive impairment and parkinsonism, however, 
clinical heterogeneity could be described between and within families with FTDP-17 [125]. 
Molecular genetic studies have identified 38 unique tau mutations in families affected by 
FTDP-17, with approximately 60% of known cases associated with P301L, N279K and a 
splice site mutation (exon 10 +16) [165].  
Mutations in tau gene associated with FTDP-17 can be divided in two groups. The 
first comprises missense mutations and deletions that have been shown to disrupt the 
binding of tau to microtubules and to accelerate its aggregation [166]. The proposed 
mechanisms involve both an increase in the proportion of tau that is unbound to 
microtubules and available for aggregation and also tau increased propensity to form 
filaments. The second group of tau mutations appears to interfere with the alternative 
splicing of exon 10 thus altering the ratio of 4R: 3R tau [167]. These mutations comprise a 
mixture of coding changes within exon 10 (e.g. N279K, P301L, P301S, N296N) and intronic 
mutations close to the 5' splice site of exon 10. Almost all of these mutations have been 
demonstrated to increase the splicing of exon 10 and consequently the proportion of 4R 
tau [125].  
Clinical features of FTDP-17 vary considerably among affected individuals, even if 
they inherit the same mutation. Indeed, members within the same family might present 
different clinical manifestations [32]. The behavioral and personality abnormalities can 
include disinhibition, apathy, defective judgment, compulsive behavior, hyper-religiosity, 
neglect of personal hygiene, alcoholism, illicit drug addiction, verbal and physical 
aggressiveness. Cognitive disturbances may impair memory, orientation, and visuospatial 
functions, progressively leading to dementia and finally mutism. Motor signs are 
 38 
 
represented by parkinsonism usually characterized by symmetrical bradykinesia, postural 
instability, rigidity and absence of resting tremor. They can manifest early or late in the 
course of the disease, sometimes misdiagnosed as Parkinson's disease (PD) or Progressive 
supranuclear palsy (PSP), or they might not be present. Up to date, no significant 
correlation between specific tau mutations and different phenotypes have been found 
[168]. 
Neuropathologically, FTDP-17 patients present atrophy of frontal and temporal 
cortex, basal ganglia and substantia nigra. In the majority of cases, these features are 
accompanied by neuronal loss, gliosis and tau inclusions in both neurons and glial cells 
(Fig. 1.12l) [164]. Different tau pathologies have been observed in different FTDP-17 
families or within the same family [169]. In some cases tau deposits are found mainly in 
neurons and contain filaments indistinguishable from AD PHFs and SFs, appearing on 
immunoblots as major bands of 60, 64, 68 kDa and a minor band of 72 kDa. However, tau 
pathology of these FTDP-17 patients differs from AD in the regional and cellular 
distribution of NFTs and NTs and by the absence of NPs [170]. Tau pathology may also 
appear on immunoblots as 2 major bands of 64 and 68 kDa and a minor band of 72 kDa, 
mainly composed of 4R tau similarly to PSP and CBD. However, tau pathology is more 
diffuse in FTDP-17 as compared to PSP and no astrocytic plaques typical of CBD have been 
observed. Therefore, the distribution of tau deposits and their structural and biochemical 
characteristics in FTDP-17 patients are different from those present in AD, PSP, CBD and 
PiD [171].  
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 Figure 1.12 Neuropathological evaluation of different tauopathies showing distinct macroscopic and 
microscopic lesions.  
a) Diffuse convolutional atrophy of the frontal, parietal and temporal lobes in AD is in contrast to b) a 
severe shrinkage of circumscribed parts of the brain in PiD, with a ‘knife-edge’ appearance of the frontal 
and anterior temporal gyri. c) CBD is characterized by atrophy of the pre- and post-central gyri (black 
arrows). d) Hippocampal AD brain section showing several flame-shaped neurofibrillary lesions (tangles) 
and neuropil threads, as well as: e) dystrophic neurites surrounding a senile plaque (neuritic plaque). (f) 
PiD granule cell layer of the dentate gyrus showing abundant intracellular Pick bodies. g) PSP 
subthalamic nucleus showing globose tangle next to several neuropil threads. h) PSP, tufted astrocyte in 
the striatum. i) CBD, cingulate gyrus showing astrocytic plaques that differs from tufted astrocytes. j) AgD 
hippocampal section showing abundant silver-stained grains. k) Next to argyrophilic grains there is also 
tau-immunoreactivity in some pyramidal cells (pre-tangled neurons). l) Frontal cortex of a case of 
Frontotemporal dementia and parkinsonism linked to chromosome 17 due to an intron 10 mutation of 
the tau gene (P301L), showing numerous tau filamentous inclusions in nerve cells and glial cells. Tau 
immunostaining also reveals a dense network of neuropil threads.  
AD PiD CBD 
AD AD PiD 
PSP PSP CBD 
AgD AgD FDTP-17 
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1.3. Synucleinopathies 
In humans, α-synuclein (αS) is encoded by SNCA gene on chromosome 4 and 
belongs to synucleins, a protein family which also include β-synuclein and γ-synuclein 
[172]. α-synuclein is a small protein comprising 140 amino acids and three domains: an N-
terminal domain (aa 1–65), a non-amyloid-β component of plaques (NAC) domain (aa 66–
95), and a C-terminal domain (aa 96–140) (Fig. 1.13). The NAC domain, which is unique to 
αS among members of the family [173], presents 12 amino acid residues that are 
responsible for the aggregation properties of α-synuclein, presumably via inhibition of its 
degradation and promoting its fibrillation [174]. 
αS have been shown to exist in various conformations in a dynamic equilibrium and 
modulated by many factors [175]; indeed, the main accepted hypothesis indicated that the 
predominant native conformation of α-synuclein might be an unstructured monomer, 
exhibiting a random coil structure in solution, while the α-helical structure might be only 
adopted upon membrane binding [176]. However, the normal physiological structure and 
function of α-synuclein still remain unclear. 
Recent studies showed that α-synuclein seems to have an important role in 
compartmentalization, storage, and recycling of neurotransmitters [176]. In addition, α-
synuclein is associated with the physiological regulation of certain enzymes and is thought 
to increase the number of dopamine transporter molecules [177]. Moreover, 
neurotransmitter release and interaction with the synaptic SNARE complex (involved in 
synaptic vesicle biogenesis) are partly mediated by its role as a molecular chaperone [176, 
178{Nemani, 2010 #6179]. 
α-synuclein misfolding and aggregation is associated with a group of diseases 
collectively known as synucleinopathies, which include Parkinson’s disease (PD), Dementia 
with Lewy bodies (DLB) and Multiple system atrophy (MSA). The majority of them are 
sporadic, however rare point mutations in the N-terminal domain of α-synuclein result in 
autosomal dominant familial Parkinson’s disease (PD) and PD-like syndromes, presumably 
caused by misfolding and aggregation of the mutant α-synuclein protein [179]. All known 
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clinical mutations are present in this N-terminal region, emphasizing the importance of this 
domain in the pathological dysfunction of α-synuclein [180]. Over 90% of aggregated α-
synuclein is phosphorylated at serine 129, while only about 4% of α-synuclein from normal 
brain is phosphorylated at this site {Fujiwara, 2002 #6380}. 
 
Figure 1.13 Schematic representation of human α-synuclein protein.  
Human α-synuclein presents an amphipathic region at the N-terminal, followed by a central NAC (non-
amyloid-β component) domain and an acidic tail at the C-terminal of the protein. The three missense 
mutations known to cause familial PD (A30P, E46K and A53T) lie in the amphipathic region, suggesting 
an important function for this region of the protein. The central hydrophobic region of α-synuclein is 
associated with an increased propensity of the protein to form fibrils. The acidic C-terminal tail contains 
mostly negatively charged residues and is largely unfolded. The most common sites of αS post-
translational modifications are depicted in red. 
 
1.3.1. Parkinson’s disease (PD) 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder 
after Alzheimer’s disease (AD), as it affected about 0.3% of the general population (Rizek 
2016). Typical onset is between the ages of 55 and 65 years and the prevalence is higher 
among men than women, for reasons still unknown, with a ratio of 1.5 to 1.0 respectively 
[181]. The etiology of PD is thought to be multifactorial, resulting from an elaborate 
interplay of genetic and environmental factors. Genetic PD account only for a limited 
number of familial (30%) and sporadic cases (3-5%), in which mutations in LRRK2 gene are 
the most frequent cause of late-onset autosomal-dominant and sporadic PD, known as 
PARK8 [182]. 
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PD is a progressive neurological disorder characterized by bradykinesia, tremor, 
rigidity and postural instability. From a neuropathological point of view, it is characterized 
by two major pathological processes: (i) premature selective loss of dopamine neurons and 
(ii) accumulation of Lewy bodies [183]. Lewy bodies are intraneuronal cytoplasmatic 
inclusions (Fig. 1.14) mainly composed of aberrant αS, which display an abnormal 
conformation promoting its aggregation, but it is also characterized by pathologic post-
translational modifications, including phosphorylation, truncation and oxidative damage 
[184]. In order to compensate for dopamine loss, the dopamine precursor Levodopa (L-
Dopa) is an effective and well-tolerated dopamine replacement agent used to improve the 
quality of life of patients with PD [185]. 
The presence of αS in cytoplasmic inclusions represents aberrant localization since it 
is normally enriched in presynaptic terminals [176]. Immunohistochemistry for αS in PD 
cases reveals the classical Lewy body pathology in vulnerable neurons of the substantia 
nigra, raphe nuclei, mesopontine tegmentum, locus ceruleus, basal nucleus of Meynert and 
dorsal motor nucleus of the vagus, but also pale staining inclusions in less vulnerable 
neuronal populations, such as those in the amygdala and neocortex [186]. These pale 
staining and poorly circumscribed lesions are referred to as pre-inclusions or cortical type 
Lewy bodies. Another major location of aberrant α-synuclein in PD is within cell processes 
(mostly axonal), so-called Lewy neuritis [187]. 
Based on neuropathologic studies, the progressive degeneration of neurons seems 
to result in the specific symptomatology of PD: when motor symptoms become evident 
there is 30–70% cell loss evident in the substantia nigra, whereas cognitive dysfunction, 
mood disorders, and impulse control disorders are related to deficits of dopamine outside 
the basal ganglia or in serotonergic and noradrenergic systems [188]. Autonomic 
dysfunction has been related to pathologies outside the central nervous system, including 
the spinal cord and peripheral autonomic nervous system. Braak and colleagues developed 
a PD-related disease staging similar to that of AD [189], showing that neuronal pathology 
occurs early in the dorsal motor nucleus of the vagus in the medulla and the anterior 
olfactory nucleus in the olfactory bulb, followed by locus ceruleus neurons in the pons and 
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then dopaminergic neurons in the substantia nigra. In later stages, pathology extends to 
the basal forebrain, amygdala and the medial temporal lobe structures, with convexity 
cortical areas affected at the end of the pathology [189]. 
1.3.2. Multiple System Atrophy (MSA) 
Multiple system atrophy (MSA) is a neurodegenerative disease characterized by a 
combination of autonomic, cerebellar, parkinsonian and pyramidal symptoms [190]. Like 
PD, the onset of MSA is usually in the sixth decade of life, but it progresses faster than 
other synucleinopathies, with a mean survival time after disease onset of 6–10 years. 
Depending on the motor phenotype, it is divided into parkinsonian (MSA-P) and cerebellar 
(MSA-C) variants, with MSA-C being usually less common than MSA-P. MSA-P is 
characterized by a hypokinetic-rigid parkinsonian syndrome, which tends to be more 
symmetrical and less responsive to Levodopa than in PD, with an irregular, higher-
frequency postural tremor. In MSA-C, the most common symptom is gait ataxia with wide-
based movements. Furthermore, ataxia of the limbs, cerebellar oculomotor impairments, 
scanning dysarthria, and intention tremor are common in MSA-C [191]. 
Proteinaceous oligodendroglial cytoplasmic inclusions (Papp-Lantos bodies) mainly 
composed of αS are the major histological hallmark of MSA (Fig. 1.14) [192], often 
accompanied by Schwann cell cytoplasmic inclusions. Unlike PD and DLB, where α-
synuclein filaments are present predominantly in the cytoplasm of nerve cells in the form 
of Lewy bodies and Lewy neurites, in MSA αS-positive inclusions are found in the 
cytoplasm and nuclei of prevalently glial cells and some nerve cells [193]. 
1.3.3. Dementia with Lewy Bodies (DLB) 
Lewy bodies disorders are dementia syndromes associated with Lewy bodies and 
are subdivided into dementia with Lewy bodies (DLB), one of the most common cause of 
dementia in the elderly together with AD and PD, and Parkinson’s disease with dementia 
(PDD), usually used to define the cognitive impairment appearing in people diagnosed 
with Parkinson’s disease [194]. The timing of dementia relative to parkinsonism is the 
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major clinical distinction between DLB and PDD, with dementia arising in the setting of 
well-established idiopathic Parkinson’s disease (after at least 1 year of motor symptoms) 
denoting PDD, while earlier cognitive impairment relative to parkinsonism denotes DLB 
[195]. 
The initial symptoms of DLB consist of a reduction in cognitive performance with 
fluctuating episodes of poor and better cognitive performance, with deficits involving the 
naming of objects, verbal fluency, visuospatial abilities, and executive functions. In contrast 
to AD, memory impairment is not a common or predominant feature in DLB in the early 
stage of the disease [196]. On the other hand, vivid, recurring or persistent visual 
hallucinations are frequent, as are delusions, lack of initiative and motivation, depressed 
moods, and anxiety. Akinetic-rigid movement disorder may already be present at the time 
of diagnosis but develops over the course of the illness in the majority of cases [197].  
Despite the different temporal sequences of motor and cognitive deficits, PDD and 
DLB show remarkably convergent neuropathological changes, including widespread limbic 
and cortical Lewy bodies and Lewy neurites composed of aggregates of α-synuclein (Fig. 
1.14), loss of midbrain dopamine cells and loss of cholinergic neurons in ventral forebrain 
nuclei [198]. The overlap of clinical, neuropsychological, and neuropathologic features has 
led to the hypothesis that PDD and DLB may be different phenotypic expressions of the 
same underlying process [199]. 
 
 
Figure 1.14 Neuropathology of α-synuclein deposits in different synucleinopathies.  
α-synuclein aggregates stained by anti-α-synuclein antibody showing different aggregates morphologies 
and distinct affected areas in PD (SN: substantia nigra),  DLB (Ctx: cortex) and MSA (CB: cerebellum; GCI: 
glial cytoplasmic inclusion). 
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1.4. Diagnosis of neurodegenerative diseases 
Diagnostic approach to neurodegenerative diseases (NDs) aims at recognizing 
pathological, biochemical and genetic biomarkers so that the diagnosis could be 
established in the early stages, allowing the stratification between different NDs and the 
identification of pre-symptomatic individuals at higher risk of developing a certain type of 
dementia [200]. 
1.4.1. Biomarkers 
 Biomarkers are biological molecular indicators of a certain disorder [201]. The 
principal requirements for a good biomarker is its preciseness and reliability, as it should 
be also able to distinguish between the healthy and the diseased patients and to 
differentiate between different diseases [202].  
Molecular and biochemical markers are evaluated based upon their sensitivity, 
specificity, positive predictive value and negative predictive value [203], whose specific 
meaning is defined in Box. 1.1. Sensitivity and specificity are statistical measures of the 
performance of a biomarker or a diagnostic method, based on the typical binary 
classification test that is widely used in medicine [204]. In this field, true or false 
terminology indicates if the assigned classification is correct or incorrect, while positive or 
negative denotes the positive or negative output of the medical test [204].  
 
Box 1.1. Statistical evaluations of the performance of a biomarker or a diagnostic method. 
 
Sensitivity  
(true positive rate) 
It refers to the ability of a biomarker to correctly identify diseased patients.  It 
measures the proportion of positives subjects that are correctly identified as 
having such condition 
Specificity 
(true negative rate) 
It refers to the ability of a biomarker to distinguish diseased patients from 
normal subjects or from other disorders. 
It measures the proportion of negative subjects that are correctly identified as 
not having the condition. 
Positive predictive 
value 
It is a measure of the percentage of people who have a positive test who can 
be shown at subsequent post-mortem examination to have the disease. 
Negative predictive 
value 
It represents the percentage of people resulting as healthy who subsequently 
at post-mortem evaluations prove to not have the disease. 
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For a clinical usage, biomarkers should have good sensitivity and specificity (e.g. 
≥90% each) [205] and a positive predictive value of approximately 80% or more [200]. 
One of the major problems in the diagnosis of NDs is the lack of a widely accepted 
sensitive diagnostic test or easily accessible biomarkers able to support neuropsychological 
evaluation, monitor disease progression and identify affected individuals in the early stages 
of the disease [206]. 
Among NDs, certain and valid biomarkers correspond to conformationally altered 
disease-associated proteins that accumulate within the brain, as previously described in 
chapters 1.2 and 1.3 [22]. Indeed, morphological and biochemical identification of disease-
specific misfolded proteins in post-mortem brain collected at autopsy is still the only 
methodology enabling to formulate a definite diagnosis of NDs [22].  
New biomarkers have been recently added in clinical diagnostic criteria for some 
NDs, such as cerebrospinal fluid (CSF) protein concentrations and imaging biomarkers 
[207]. However, for many NDs the autoptic confirmatory test is not required, thus the 
validity of such biomarkers are still under debate. Neuroimaging techniques using 
structural magnetic resonance imaging (MRI) of gray matter and diffusion tensor imaging 
(DTI) of white matter within the context of autopsy-confirmed clinical FTD found some 
regional differences between subtypes of FTLD-Tau and FTLD-TDP [208], nevertheless, only 
one study have been performed. Several radio-ligands specific for tau pathology have 
been recently developed to detect and track the progression of tau pathology in living 
patients [209], however, no specific discrimination between different tauopathies is 
currently possible [210]. Thus, diagnosis of FTLD syndromes is based only on clinical 
symptoms and is hampered by the great overlap of the clinical manifestation within the 
FTLD subtypes and with other types of dementia [211]. 
CSF analysis has been performed with the aim of finding protein biomarkers, 
however, the largest body of data exists mainly for AD cases and few studies have been 
validated for other NDs. The AD CSF signatures are elevated tau and phospho-tau 
concentrations and decreased Aβ42 levels, which have been shown to differentiate AD from 
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healthy subjects [212] and may help in distinguishing atypical forms of AD pathology 
associated with clinical FTD from those with underlying FTLD-Tau pathology [213].  
Some biomarkers of genetic susceptibility have been also evaluated, such as the 
presence in a patient with dementia of one or more ε4 alleles of the gene for 
apolipoprotein E (APOE ε4) which has been significantly associated with Alzheimer's 
disease (AD) [214]. However, APOE genotyping does not provide sufficient sensitivity or 
specificity when used alone as a diagnostic test for AD but improves the specificity of 
diagnosis when used in combination with clinical criteria [215].  
1.4.2. Probable or possible diagnosis  
Probable or possible diagnosis of NDs might be made on the basis of international 
consortium guidelines, which reviewed clinical records and compared the sensitivity and 
specificity of proposed diagnostic criteria with neuropathologically verified cases of NDs 
[30]. According to the revised criteria, probable diagnosis is usually made in cases that 
match a significant number of proposed clinically discriminating features, whereas possible 
diagnosis is made in cases presenting atypical clinical manifestations [30, 216].  
Probable or possible diagnosis of different NDs focuses primarily on the evaluation 
of clinical signs and on the anatomical distribution of neuronal loss. In most NDs cases, 
clinical symptoms show a high degree of similarity and usually overlap during the course 
of the disease [19]. However,  initial clinical symptomatology may reflect the anatomical 
distribution of neuronal loss and may be useful for disease discrimination [217]. Based on 
initial clinical manifestations, neurodegenerative disorders may be divided in two different 
groups presenting: 
1. cognitive decline, dementia and alterations in high-order brain 
functions (DEM/FTD phenotype): these symptoms are associated with 
involvement of the entorhinal cortex, hippocampus, limbic system, and 
neocortical areas. The DEM/FTD phenotype is mainly associated with FTD and 
its subtypes (PSP, CBD, PiD, FTLD), Alzheimer’s disease (AD), Huntington's 
disease (HD) and Dementia with Lewy bodies (DLB) [20]. Cognitive 
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impairment is detected and diagnosed through a combination of (1) history-
collection from the patient and a knowledgeable informant and (2) an 
objective cognitive assessment, such as a mental status examination or 
neuropsychological testing [216]. 
2. movement disorders (MD phenotype): associated with the involvement of 
basal ganglia, thalamus, brainstem nuclei, cerebellar cortex and nuclei, motor 
cortical areas and lower motor neurons of the spinal cord. The MD 
phenotype is usually observed in motor neuron diseases (MND) such as ALS 
and SCA, and in Parkinson’s disease (PD), however atypical parkinsonisms 
such as PSP and CBD usually display motor deficits and they also might 
appear in the late stages of FTD  [3].  
Although numerous effort has been made in the establishment of consensus 
criteria, the diagnosis of NDs has been shown some degree of inaccuracy (Table 1.3) [218].  
Indeed, twenty-five percent of patients clinically diagnosed with probable AD during their 
lifetime were not confirmed at autopsy. Thus, diagnostic accuracy is 77% for a clinical 
diagnosis of AD [219]. 
Table 1.3 Diagnostic accuracy of current clinical diagnostic criteria for different neurodegenerative 
diseases. 
Neurodegenerative  
disease 
Diagnostic 
accuracy 
References 
Alzheimer’s disease (AD) 77% 
Marwan N. Sabbagh, et al. Neurol Ther (2017) 6 (Suppl 
1):S83–S95 ; Guy M. McKhann, et al. Alzheimers Dement. 
2011 May; 7(3): 263–269. 
Parkinson’s disease (PD) 80% Postuma R.B., et al. Mov Disor (2015) 30, 12:1591 - 601 
Dementia with Lewy bodies 
(DLB) 
80% 
Rizzo G., et al. J Neurol Neurosurg Psychiatry. 2018 
Apr;89(4):358-366. 
Frontotemporal dementia 
(FTD) 
90% 
Balasa M., et al. Neuropathol Appl Neurobiol. 2015 
Dec;41(7):882-92. 
Multiple system atrophy 
(MSA) 
62% Gilman S., Neurology. 2008 Aug 26;71(9):670-6. 
Corticobasal degeneration 
(CBD) 
68% Armstrong M.J., Neurology. 2013 Jan 29;80(5):496-503. 
Progressive supranuclear 
palsy (PSP) 
95% Hoglinger G.U., Mov Disorder. 2017 Jun;32(6):853-864. 
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Even though the clinical diagnosis of parkinsonism might be relatively simple, the 
specific diagnosis of PD, especially at the early stages, can be difficult. It has been reported 
that in patients with possible PD only 26% had autopsy confirmation, while in probable PD 
the diagnostic accuracy was 82% [220]. In DLB, clinical diagnostic criteria for probable DLB 
identify αS pathology with a sensitivity of about 80%, however, early diagnosis is less 
accurate due to the overlapping symptoms with other types of dementia [221]. In addition, 
15–20% of patients with confirmed AD at autopsy showed concomitant DLB pathology, 
with only a minority of patients exhibiting clear diagnostic features of DLB [222].  
1.4.3. Definite diagnosis 
Definite diagnosis of NDs is based on the evaluation of histological features (e.g., 
vascular lesions or neuronal loss) and on the presence of intracellular and extracellular 
protein accumulations, which are analyzed by immunohistochemistry complemented by 
biochemistry in post-mortem tissues [20]. 
For the definite diagnosis of AD, stages of neurofibrillary degeneration and phases 
of Aβ deposition are evaluated by immunohistochemistry techniques, as protein pathology 
in AD usually follows a stereotypical pattern of deposition that was conceptualized by 
Braak and colleagues [146]. Areas showing tau pathology include the transentorhinal 
cortex (stage I), entorhinal cortex (stage II), inferior (stage III) and middle temporal gyri 
(stage IV), while in the end stages the occipital cortex is involved (stage V-VI). Regarding 
Aβ deposition, five phases were proposed by the progressive involvement of isocortical 
areas (phase 1), hippocampus and entorhinal cortex (phase 2), basal ganglia and 
diencephalon (phase 3), brainstem (phase 4) and cerebellum (phase 5). Together with the 
classical semiquantitative scoring of neuritic plaques, tau and Aβ pathology stages are 
included in the recent NIA-AA neuropathological criteria for AD [223]. 
Definite diagnosis of different subtypes of tauopathy is mainly based on the 
positivity for misfolded hyperphosphorylated tau and on the cellular distribution of tau 
pathology: PiD, AD, NFT-dementia/PART are disorders showing neuronal tau inclusions, 
whereas mixed neuronal and glial tau deposits can be found in PSP, CBD and AGD [28]. 
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Some specific morphological features are assessed, such as the presence of round tau-
positive “Pick bodies” in neurons that are typical of PiD, CBD-associated ballooned neurons 
and astrocytic plaques which are different from tufted astrocytes particularly found in PSP 
cases [224]. Final diagnosis may employ also biochemical evaluation of tau isoforms by 
Western blot analysis of insoluble tau extracted from post-mortem brain tissues, thus 
differentiating through their banding pattern tau pathology associated with 3R or 4R 
isoforms and mixed 3R+4R types, as shown in Chapter 2.1 [225]. 
Regarding the definite diagnosis of synucleinopathies, cellular localization of αS 
deposits by immunohistochemistry techniques is employed for disease discrimination. 
Indeed, DLB and PD shows predominance of intraneuronal cytoplasmic and neuritic 
deposits (cortical and brainstem type Lewy bodies and Lewy neurites), whereas MSA is 
dominated by glial cytoplasmic inclusions (Papp-Lantos bodies) [195]. In spite of studies 
suggesting that the biochemical pattern of αS may differ in distinct α-synucleinopathies 
[226], there are however no biochemical or morphological features that allow unequivocal 
distinction of potential molecular subtypes of abnormally folded αS [20]. 
1.4.4. RT-QuIC and PMCA technologies  
The recent advances in molecular and structural biology have provided insights into 
the processes involved in the pathogenesis of neurodegenerative diseases and have made 
it possible to recapitulate the protein misfolding process in vitro in a limited period of time 
through the development of innovative techniques. 
These new methodologies exploit the ability of misfolded proteins to transmit their 
abnormal conformation to normal monomers, which are used as substrate of reaction 
[227].  Abnormally folded proteins are able to interact with these substrates and induce 
monomers to change conformation and subsequently aggregate. Therefore, the addition 
of misfolded proteins to the substrate is able to trigger an aggregation phenomenon that 
might be exploited for a diagnostic and therapeutic point of view. The technologies that I 
will be describing here, are extremely sensitive and the aggregation phenomenon is 
triggered even by trace-amount of abnormally folded proteins.   
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These abnormally folded proteins are considered “seeds” and their ability to 
promote monomers aggregation is known as “seeding effect”. These techniques were 
originally developed in the field of prion diseases to amplify undetectable amount of PrPSc, 
however, their applicability for protein misfolding studies in other NDs is very promising. 
Protein Misfolding Cyclic Amplification (PMCA) assay is performed in a test-tube 
and consists of cycles of incubation and sonication (Fig. 1.15) [228]. During the incubation 
phase, the sample containing minute amounts of PrPSc is incubated with an excess of PrPC 
to induce growing of PrPSc polymers. In the second phase, the sample is subjected to 
sonication to break down the polymers and to multiply the number of nuclei. After each 
cycle, the number of seeds increases in an exponential fashion, thus accelerating the 
seeding-induced conversion of PrPC into PrPSc [229]. Normal mammalian brain 
homogenate is typically used as a source of PrPC, whereas any tissue homogenate or 
biological fluid suspected to contain prions constitutes the seed of the reaction. Final 
products of the reaction are subjected to mild proteolysis digestion with Proteinase K (PK) 
in order to completely degrade PrPC and to visualize PK-resistant PrPSc by immunoblot 
using anti-PrP antibodies.  
PMCA technique has been shown to detect and amplify as little as a single molecule 
of oligomeric infectious PrPSc eventually contained in a sample [230]. PMCA amplified 
products have been shown to exhibit the same biochemical, biological and structural 
properties as brain-derived PrPSc and to be infectious when injected into wild-type animals, 
producing a disease with similar characteristics as the illness produced by brain-isolated 
prions [231]. PMCA allows the faithful replication of prion strains in many different species 
of prions, however, it is also possible to use PrPC from one species to replicate prions from 
a different species thanks to the extremely high flexibility of PrP [232].  
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Figure 1.15. Schematic representation of Protein Misfolding Cyclic Amplification (PMCA). 
PMCA consist of cycles of incubation and sonication steps that can exponentially amplify minute 
amounts of PrPSc through the conversion of PrPC provided as substrate. Western blot (WB) analysis 
revealed that, after the amplification, it is possible to detect trace-amount of prions undetectable before 
PMCA (left bottom panel). 
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Real-Time Quaking Induced Conversion (RT-QuIC) is another extremely sensitive 
technique based on the same principle, the seeding-nucleation propagation of misfolded 
proteins (Fig. 1.16). RT-QuIC assay is performed in a multi-well plate, in which the reaction 
substrate is usually a recombinant or synthetic protein and amyloid formation is monitored 
by Thioflavin T (ThT), an amyloid-specific fluorescent dye similar to Thioflavin S (ThS). Upon 
binding to amyloid fibrils, the central C–C bond connecting the benzothiazole and aniline 
rings of ThT molecule is immobilized and fluorescence signal strongly increases when 
excited at 450 nm, detected at approximately 482 nm [233]. In RT-QuIC assay, the substrate 
is usually prone to aggregate, however, the fibrillization reaction is notably accelerated by 
the presence of pre-formed aggregates in a given sample. Therefore, in seed-containing 
reactions lag phase is reduced and ThT fluorescence levels exponentially increase [234]. 
1.4.5. Contribution of RT-QuIC and PMCA in diagnostics 
Recent observations suggested that very low concentrations of disease-specific 
biomarkers could be present in peripheral tissues of patients with NDs. If this was the case, 
their identification would be fundamental for formulating a definite diagnosis in the early 
stages of the diseases thus enabling patient’s stratification. Moreover, these tissues can be 
periodically collected and might allow to monitor disease progression and evaluate the 
effects of specific drugs in patients under pharmacological treatments. As previously 
described (chapter 1.3), an important role in biomarkers spreading seems to be played by 
exosomes.  
The advent of these cell-free amplification technologies (RT-QuIC and PMCA) 
provided the first evidence that trace-amount of such biomarkers are effectively detectable 
in peripheral tissues and body fluids of patients with different NDs, such as CSF, urine and 
olfactory mucosa (OM) (Fig. 1.17). 
It has been shown that PMCA is capable of detecting as little as a single molecule of 
oligomeric infectious PrPSc, thus opening a great promise for the development of a highly 
sensitive detection method for prions and for understanding the molecular basis of prion 
replication. 
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Figure 1.16 Schematic representation of Real-Time Quaking Induced Conversion (RT-QuIC). 
In RT-QuIC assay, the formation of aggregates of recombinant PrP (rec-PrP) is induced by the addition 
of low amount of PrPSc and is accelerated by cycles of shaking and incubation. Amyloid formation is 
monitored in real-time using ThT fluorescent dye. Rec-PrP usually do not fibrillate spontaneously (gray 
line, right bottom panel), however the addition of PrPSc-containing samples induced its aggregation in a 
dose-dependent manner (orange lines, right bottom panel). 
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Indeed, PMCA has been used by various groups to detect PrPSc in blood of animals 
experimentally infected with prions during both symptomatic [235] and pre-symptomatic 
[236] phases of the disease. The technique was then optimized as a non-invasive method 
for early diagnosis of prion diseases in humans. PMCA assay displayed 100% sensitivity and 
specificity in the detection of PrPSc in blood of pre-symptomatic [237] and symptomatic 
vCJD patients [238]. PMCA was also employed to detect PrPSc in the urine of patients with 
vCJD with an estimated sensitivity of 93% and a specificity of 100% [239] and in the CSF of 
vCJD patients with 100% sensitivity and specificity ([240]. Moreover, PMCA coupled with a 
new detection method (SOFIA) allows identifying the presence of PrPSc in CSF of patients 
with sCJD with 100% sensitivity and 100% specificity [241].  
 
Figure 1.17 Peripheral tissues and body fluids potentially containing abnormally folded proteins. 
Cerebrospinal fluid (CSF), olfactory mucosa (OM) and urine are accessible specimens that could be 
tested through PMCA and RT-QuIC assays for the detection of seeding activity exerted by misfolded 
proteins. 
 
Several research groups have carried out large studies in which CSF samples 
collected from CJD patients were evaluated using RT-QuIC assays, showing the ability to 
detect prion seeding activity with sensitivity ranging from 77–97% and specificity of 99–
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100% [234, 242]. Some slight variations in RT-QuIC protocol with respect to reaction buffer 
composition, temperature, shaking motion and speed, and recombinant PrPC substrate 
may influence the sensitivity and specificity of the test [243]. Indeed, the first generation of 
this assay mainly used full-length (23–231) hamster recombinant prion protein (rPrPsen) as 
RT-QuIC substrate, demonstrating a very high specificity but a suboptimal sensitivity, 
whereas Orrù and colleagues recently introduced a second-generation RT-QuIC assay for 
sCJD CSF which uses a truncated form of hamster recombinant PrP (rPrPsen, amino acids 
90–231) thus improving diagnostic sensitivity and shortening the testing time [244, 245].  
Recently, RT-QuIC assay has been optimized to detect Aβ seeding activity in CSF of 
patients with AD, with a sensitivity of 90% and specificity of 92%. In this study, Soto and 
colleagues were able to detect as little as 3 femtograms of Aβ oligomers [246], showing 
the potential application of RT-QuIC technique in detecting misfolded proteins other than 
prion. Moreover, Caughey and colleagues developed an RT-QuIC assay able to detect 3R 
tau seeds in CSF of patients with Pick’s Disease (PiD) with 100% sensitivity and 98% 
specificity [247]. 
Similar assays have been developed to detect αS seeding activity in body fluids of 
patients with synucleinopathies. For instance, an RT‐QuIC‐based assay was able to detect 
αS aggregation in CSF collected from patients with DLB and PD, characterized by a 
sensitivity of  92% and 95%, respectively, and with an overall specificity of 100% when 
compared to AD and healthy controls [248]. Similarly, Soto and colleagues developed an 
RT-QuIC assay to distinguish CSF samples obtained from patients affected by PD from 
those collected from individuals affected by other neurologic diseases. Results showed that 
they were able to correctly identify patients affected by PD with an overall sensitivity of 
88.5% and specificity of 96.9%. Moreover, kinetics parameters of the RT-QuIC reaction 
correlated with disease severity in the PD group [249].  An improved αS RT-QuIC assay has 
been developed that has similar sensitivity and specificity to the prior assays but can be 
performed in a shorter period of time. Moreover, it allows the quantitation of relative 
amounts of αS seeding activity in a very small quantity of CSF samples [250]. Finally, our 
research group has recently published an article showing that even olfactory mucosa 
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samples collected from patients with PD and MSA efficiently triggered -synuclein 
aggregation by means of RT-QuIC  [251], thus suggesting that such tissue can be exploited 
for diagnostic purposes.  
The olfactory mucosa was chosen on the basis of several preliminary results 
obtained in the prion field. Indeed, prions were found in the olfactory neuroepithelium of 
CJD patients collected post-mortem [252] and it has been shown that olfactory mucosa 
(OM) was an important tissue for antemortem diagnosis of NDs based on RT-QuIC assay. 
Indeed, RT-QuIC analysis of OM samples collected from 43 CJD patients showed levels of 
PrPSc seeding activity that were orders of magnitude higher (97.5% sensitivity and 100% 
specificity) than those observed in the CSF collected from the same patients (77% 
sensitivity and 99% specificity  [253]. 
Our group also investigated the presence of prions in OM from patients with Fatal 
Familial Insomnia (FFI), revealing that OM specimens collected from two patients with FFI 
display prion-seeding activity that is detectable by both RT-QuIC and PMCA [254]. 
Although FFI is a genetic disorder, the evaluation of prion seeding activity through OM 
analysis might be helpful in assessing the progression of the pathology and in monitoring 
the efficacy of therapeutical applications.  
1.4.6. Contribution of RT-QuIC and PMCA in therapeutics  
PMCA and RT-QuIC methodologies have been also exploited to screen for 
molecules displaying anti-protein aggregation activities. Both techniques can be used to 
evaluate the effects and the mechanisms of inhibitors of misfolding proteins formation and 
propagation in vitro.  
Indeed, RT-QuIC assay has been used to analyze the impact of specific substances 
(e.g. doxycycline) on the conversion and aggregation of PrPSc in vitro [255]. Doxycycline 
was added in different concentrations and at different times to the RT-QuIC reaction mix 
seeded with brain tissue or CSF from sCJD and control patients. They showed that the 
addition of doxycycline results in a dose- and time-dependent inhibition of the RT-QuIC 
seeding activity exerted by brain and CSF samples of patients with sCJD. In contrast, other 
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tested molecules (e.g. ampicillin and sucrose) did not show any effect on RT-QuIC seeded 
reactions.  
Spillantini and colleagues set up a highly efficient PMCA for α-synuclein and tested 
the ability of 10 compounds with proven anti-amyloid activity to interfere with αS 
aggregation. They showed that αS aggregation in PMCA was strongly inhibited by Congo 
red, curcumin, resveratrol and to a lower extent by epigallocatechin gallate (EGCG), tannic 
acid and lacmoid [256].  
We have also contributed to analyze the effects that 2,4-thiazolidinedione 
derivatives exerted on tau aggregation by means of RT-QuIC [257]. Thiazolidinediones are 
sulfur-containing pentacyclic compounds that gained the researcher's attention as they are 
widely present in nature and exhibited antimicrobial, anticonvulsant, antiviral, anticancer, 
anti-inflammatory and antioxidant properties, thus being involved in the control of various 
physiological activities [258]. In this work, one of these compounds was able to reduce 
tauK18 (4R) and full-length tau (2N4R) aggregation in RT-QuIC, thus demonstrating that 
this technique can be efficiently used for a preliminary assessment of the efficacy of anti-
aggregation compounds.  
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CHAPTER II 
 
AIM OF THE STUDY 
 
Aim of my PhD work was to evaluate the ability of Real-Time Quaking Induced Conversion 
(RT-QuIC) technology to detect seeding activity of misfolded tau protein eventually 
present in peripheral tissues, such as olfactory mucosa (OM) and body fluids (urine and 
cerebrospinal fluid) collected from patients with primary (FTDP-17, FTD, PSP, CBD) and 
secondary (AD) tauopathies. Since the diagnosis of PSP and CBD is often challenging 
(especially in the early stages) because it might be confused with other parkinsonisms, I 
have included in my analysis samples belonging to patients with different 
synucleinopathies (MSA, PD, and DLB). In particular, I have firstly optimized RT-QuIC 
experimental settings for tau K18 aggregation and I have then exploited the assay for the 
analysis of biological samples (brain, olfactory mucosa, CSF and urine) collected from 
inpatients and outpatients with a clinical diagnosis of AD, PSP, CBD, FTDP-17, FTD, MSA, 
PD and DLB visiting Carlo Besta Institute for diagnostic or therapeutic purposes. Final RT-
QuIC products have been subjected to biophysical analysis to verify whether they have 
acquired “strain” specific features eventually useful for stratifying patients with AD, PSP, 
and CBD.  
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CHAPTER III 
MATERIALS AND METHODS 
3.1. tauK18 RT-QuIC aggregation protocol optimization 
Recombinant tauK18 was diluted in different reaction mixes in order to find the best RT-
QuIC aggregation protocol. All reactions were supplemented with 10 µM of Thioflavin-T 
(ThT) as fluorescent amyloid dye. Heparin (heparin sodium salt from porcine intestinal 
mucosa, Sigma-Aldrich) was also added in all reaction mixes in a molar ratio 
heparin:tau=~1:4. tauK18 was initially diluted at a concentration of 8 μM in 1X PBS (pH 7.4, 
Sigma-Aldrich) or in 10 mM piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES, pH 6.5, 
Sigma-Aldrich) buffer and supplemented with 50 μg/ml heparin and 0.1 mM 1,4-
Dithiothreitol (DTT, Sigma Aldrich). Subsequently, different biochemical and biophysical 
conditions were tested: i) 4 μM and 8 μM tauK18, ii) absence or presence of 0.1 mM DTT, 
(iii) 1’ or 14’ of incubation time. The resulting reaction mixes were composed as described 
below and summarized in Table 3.1: 
 8 μM tauK18 + 50 μg/mL heparin + 0.1 mM DTT in PBS buffer (#1 and #5);  
 4 μM tauK18 + 25 μg/mL heparin + 0.1 mM DTT in PBS buffer (#2 and #6);  
 8 μM tauK18 + 50 μg/mL heparin in PBS buffer (#3 and #7);  
 4 μM tauK18 + 25 μg/mL heparin in PBS buffer (#4 and #8).  
Reactions were performed in a black 96-well optical flat bottom plate (Thermo Scientific), 
where each well was supplemented with 100 μL of reaction mix. The plate was sealed with 
a sealing film (Thermo Scientific), inserted into a FLUOstar OPTIMA microplate reader 
(BMG Labtech) and subjected to cycles of 1’ shaking (600 rpm, double orbital) and 1’ 
incubation at 37 °C (#1, #2, #3, #4) or 1’ shaking (600 rpm, double orbital) and 14’ of 
incubation (#5, #6, #7, #8), as described in Table 3.1.  
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Table 3.1 Biochemical and biophysical conditions tested during the optimization of RT-QuIC tauK18 
aggregation protocol. 
 1’ shaking + 1’ incubation 1’ shaking + 14’ incubation 
 + DTT - DTT + DTT - DTT 
8 μM tauK18 #1 #3 #5 #7 
4 μM tauK18 #2 #4 #6 #8 
 
Fluorescent intensities, expressed as arbitrary units (AU), were taken every 30 minutes 
using 450 ± 10 nm (excitation) and 480 ± 10 nm (emission) wave-lengths and plotted in a 
graph against time. 
3.2. In vitro generation of tauK18, tauK19, αS, Aβ1-40 and  Aβ1-42 PFFs 
Condition #1, among the previously described in Paragraph 3.1, was chosen to generate 
tauK18 aggregates, named tauK18 pre-formed fibrils (tauK18 PFFs). The presence of 
tauK18 amyloid fibrils was confirmed by negative staining and Transmission Electron 
Microscopy (TEM) analysis or by classical staining with amyloid-specific dye, such as Congo 
Red, ThT and Thioflavin-S (ThS). tauK19 (3R-tau fragment), αS, Aβ1-40 and  Aβ1-42 pre-
formed fibrils (PFFs) were generated by diluting each recombinant protein (αS, tauK19) or 
synthetic protein fragment (Aβ1-40 and  Aβ1-42) in its aggregation buffer, previously 
established in our laboratory. In particular, αS was diluted at 35 μM in 1X PBS buffer and 
supplemented with 0.1 M NaCl (Sigma) and 10 μM ThT. tauK19 (3R tau fragment) was 
diluted at 45 μM in 1X PBS buffer and supplemented with 50 μg/mL low molecular weight 
heparin (Fisher Scientific) and 10 μM ThT. Aβ1-40 and  Aβ1-42 were diluted at 5 μM and 10 
μM, respectively, in 100 mM Tris-HCl buffer (pH 7.4, Carlo Erba) and supplemented with 10 
μM ThT. Each aggregation reaction was performed in RT-QuIC as previously described in 
Paragraph 3.1 by subjecting samples to cycles of 1’ shaking and 1’ incubation. The 
presence of amyloid fibrils in all RT-QuIC reaction products was confirmed by TEM and 
they were named αS PFFs, tauK19 PFFs, Aβ1-40 PFFs, and  Aβ1-42 PFFs. Samples were diluted 
at a final concentration of 5 µM and used for RT-QuIC analysis. The fibril concentrations 
were considered to be the same as the starting monomer concentration, with the 
assumption of complete conversion from monomers to fibrils. 
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3.3. In vitro generation of oligomers, early-fibrils, and late-fibrils of αS and 
tauK18 
Recombinant αS was diluted at 20 μM in ultrapure water, supplemented with 10 μM ThT 
and induced to self-assembly by means of RT-QuIC, as previously described in Paragraph 
3.1 (cycles of 1’ shaking and 1’ incubation). At different time points of the aggregation 
kinetics, one aliquot of the reaction mix was collected and analyzed by TEM to assess the 
presence of oligomers and fibrils. Early-fibrils were collected during the exponential phase 
of αS aggregation kinetics, whereas late-fibrils were collected when the reaction reached 
the plateau. tauK18 oligomers, early-fibrils, and late-fibrils were also generated by inducing 
tauK18 self-assembly in RT-QuIC as previously described (condition #1, Paragraph 3.1) and 
collecting one aliquot at different time points of the aggregation kinetics. The presence of 
such species in tauK18 aliquots was assessed by TEM. 
3.4. In vitro generation of different αS PFFs  
Distinct αS PFFs (#1, #2, #3 and #4) were generated by diluting recombinant αS at 20 μM 
in different aggregation buffers, composed as follows: 
 Ultrapure water (αS PFFs#1) 
 5 mM Tris-HCl (αS PFFs#2) 
 5 mM Tris-HCl + 150 mM KCl (αS PFFs#3) 
 5 mM Tris-HCl + 100 mM NaCl (αS PFFs#4) 
All reactions were supplemented with 10 µM of ThT and were subjected to self-assembly in 
RT-QuIC, as previously described (Paragraph 3.1, cycles of 1’ shaking and 1’ incubation). 
Samples were partially digested with proteinase K (PK) and analyzed by Silver staining or 
visualized by TEM. αS PFFs (#1, #2, #3 and #4) were then collected and used as seed in RT-
QuIC. 
3.5. Amyloid-specific stainings of tauK18 PFFs 
Two μL of tauK18 PFFs were deposited onto poly-l-lysine coated slides and dried at room 
temperature (RT). Congo Red staining solution was prepared by dissolving Congo Red 
(Sigma-Aldrich)  at 0.5% (w/v) in 50% ethanol (EtOH). tauK18 PFFs slides were incubated 
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with Congo Red solution for 20’ and washed quickly with 100% EtOH. Slides were 
dehydrated in 100% xylene two times (2’ each) and coverslips were mounted with Eukitt 
mounting medium (Bio-Optica Milano S.p.A.). Thioflavin-S (ThS) and ThT solutions were 
prepared by dissolving ThS at 1% (w/v) and ThT at 1 mM in ultrapure water (Sigma). 
tauK18 PFFs slides were incubated with ThS and ThT solutions for 10’ and washed three 
times with PBS 1X for 1’. Once dried at RT, coverslips were mounted using glycerol 
mounting medium (Merck Millipore). Bright-field images were acquired with (⊕) or 
without (⊖) polarizing filters at 40X magnification with a Nikon Eclipse E800 microscope 
equipped with Nikon digital camera DXM 1200 and Nikon ACT-1 (v2.63) acquisition 
software. Fluorescence images of tauK18 PFFs fibrils stained with ThT and ThS were imaged 
using the same microscope equipped with mercury lamp light source. 
3.6. Preparation of brain samples for RT-QuIC analyses 
Frontal cortices of patients with neuropathologically confirmed diagnoses of 
Frontotemporal dementia and parkinsonism linked to chromosome 17 associated with 
P301L tau mutation (FTDP-17, n=1), Progressive supranuclear palsy (PSP, n=1), Alzheimer’s 
disease (AD, n=1), Dementia with Lewy bodies (DLB, n=1) and from a Non-demented 
patient (NDP, n=1) were homogenized in PBS at 10% (weight/volume) using a glass potter 
homogenizer. Samples were centrifuged (Eppendorf Centrifuge 5415R) at 800 × g for 1‘ at 
4 °C to remove cellular debris. Collected supernatants were identified as brain 
homogenates (BH) and stored at −20 °C for RT-QuIC analysis.  
3.7. Extraction of insoluble tau from brain samples 
Insoluble tau was extracted from the over-mentioned brain tissue samples as previously 
described [89]. Briefly, approximately 200 mg of frontal cortex were homogenized at 10% 
(weight/volume) of extraction buffer containing: 10 mM Tris-HCl pH 7.4 (Carlo Erba), 0,8 M 
NaCl (Carlo Erba), 1 mM EDTA (Sigma-Aldrich), 10% sucrose (Carlo Erba), 0,1% sarkosyl 
(Sigma-Aldrich). Two aliquots of 900 µL for each sample were processed as follow: each 
aliquot was centrifuged at 10’000 × g for 10’ at 4°C (Eppendorf centrifuge 5415R), pellets 
were re-extracted twice using 250 µL of the same extraction buffer and supernatants from 
 64 
 
all three extractions (S1, S2, and S3) were retained and pooled. Pooled supernatants of 
both aliquots were collected together and sarkosyl was added to reach a final 
concentration of 1%. Samples were incubated for 1 hour at 37°C under rotation (TAAB 
rotator type N). Samples were divided in 2 aliquots of 1 mL and each aliquot was 
centrifuged for at 300’000 × g for 1 hour at 4°C (Beckman TLA 120.2). Each pellet was re-
suspended in 100 µL of PBS 1X and briefly sonicated (sonicator Q700, Qsonica). Pellets 
were pooled (200 µL) and further centrifuged at 10’000 × g for 30’ at 4°C to remove large 
debris. Supernatants containing PHF-tau were analyzed by bicinchoninic acid (BCA) assay 
(ThermoFisher Scientific) for total protein concentration and stored at −20 °C. 
3.8. Conformational stability assay 
Two hundred and fifty ng of PHF-tau extracts were denatured with the following 
concentrations of Guanidine hydrochloride (GdnHCl) for 30 min at 37°C: 0 M, 1 M, 2 M, 
and 3 M. Samples were diluted 1:3 and digested with 1 μg/μl of PK for 30’ at 37°C, 
followed by centrifugation at 45’000 rpm for 30’. Pellets were re-suspended in 20 μL of LDS 
loading buffer for Western blot analysis. Densitometric analysis of PHF-tau PK resistance 
after denaturation with different concentrations of GdnHCl was performed using ImageJ 
software (1.48v). 
3.9. Proteinase K digestion 
Twenty microliters of final tauK18 RT-QuIC products were treated with 20 μg/mL of 
Proteinase K (PK, Invitrogen) for 30’ at 37 °C under shaking (550 rpm). αS PFFs#1, #2, #3 
and #4 were digested with 1 μg/mL of PK for 1 hour at 37 °C under shaking (550 rpm). 
Digestion was stopped directly by the addition of LDS-PAGE loading buffer and analyzed 
by Western blot or Silver staining. 
3.10. Silver staining 
Samples were supplemented with LDS loading buffer (Invitrogen), heated at 100 °C for 10 
minutes and loaded into 12% Bolt Bis-Tris Plus gels (Invitrogen). Proteins were separated 
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by means of SDS-PAGE and visualized directly on polyacrylamide gels by Pierce Silver Stain 
Kit (ThermoFisher Scientific). 
3.11. Western blotting 
Samples were supplemented with LDS loading buffer (Invitrogen), heated at 100 °C for 10 
minutes and loaded into 12% Bolt Bis-Tris Plus gels (Invitrogen). Proteins were separated 
by means of SDS-PAGE, transferred onto Polyvinylidene difluoride (PVDF) membranes 
(Immobilon-P, Millipore) and incubated with 5% (weight/volume) non-fat dry milk 
(prepared in Tris-HCl with 0.05% Tween-20) for 1 hour at room temperature under shaking. 
PVDF membranes were incubated overnight at 4°C under shaking with PHF-6 antibody 
(phosphorylated tau at Thr231 mouse monoclonal antibody, Thermo Fischer Scientific) or 
with RD4 antibody (4-repeat isoform tau mouse monoclonal antibody, clone 1E1/A6, 
Thermo Fischer Scientific) to visualize PHF-tau extracts or final RT-QuIC products, 
respectively. Membranes were also incubated with mouse monoclonal antibody against 
exosomal marker CD63 (Thermo Fischer Scientific). Finally, membranes were incubated 
with anti-mouse secondary antibody conjugated with horseradish peroxidase (GE) and 
developed with a chemiluminescent system (ECL Prime). Reactions were visualized using a 
G:BOX Chemi Syngene system. 
3.12. Collection and preparation of olfactory mucosa samples 
A total number of 24 samples of olfactory mucosa (OM) were collected from patients with 
clinical diagnosis of Frontotemporal dementia and parkinsonism linked to chromosome 17 
associated with P301L tau mutation (FTDP-17), Progressive supranuclear palsy (PSP), 
Corticobasal degeneration (CBD), Alzheimer’s disease (AD), genetic AD (gAD, PSEN1 
mutation), Dementia with Lewy bodies (DLB), Parkinson’s disease (PD), genetic PD (gPD, 
PARK8 subtype), Multiple system atrophy (MSA) and Multiple sclerosis (MS). The number 
of OM samples collected for each condition and the acronym used in this study is 
summarized in Table 3.2. 
Before collection, the nasal cavity was treated with a topical anesthetic (Ecocain, Molteni 
Dental) for 10 minutes. OM were collected from the medial turbinate of each nasal cavity 
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using a cotton swab (FLOQSwabsTM Copan Italia, Brescia, Italy) through a procedure called 
nasal brushing, as previously described [253, 254]. After collection, both cotton swabs were 
immersed in saline solution and vortexed 3 times for 1’ to separate olfactory cells from the 
cotton swab. Suspended cells were pelleted at 800 × g for 20’ at 4 °C, the supernatant was 
removed and OM was stored at −80 °C.  For RT-QuIC analysis, approximately 2 μg of 
pellets were collected with the use of inoculating loops. Such material was then transferred 
into a tube containing 25 μL of PBS and used for RT-QuIC analyses.  
Table 3.2. List of OM samples analyzed in this study, showing patient clinical diagnosis and acronym 
used. 
Number of 
OM samples 
Clinical diagnosis Acronym 
Primary Tauopathies 
2 Frontotemporal dementia and parkinsonisms linked to 
chromosome 17 (P301L mutation) 
FTDP-17 
4 Progressive supranuclear palsy PSP 
2 Corticobasal degeneration CBD 
Secondary Tauopathies 
2 Alzheimer’s disease AD 
1 Genetic Alzheimer’s disease 
(PSEN1 mutation) 
gAD (PSEN) 
Synucleinopathies 
2 Genetic Parkinson’s disease 
(PARK8 subtype) 
gPD (PARK8) 
2 Parkinson’s disease PD 
2 Multiple system atrophy MSA 
2 Dementia with Lewy bodies DLB 
Other conditions 
2 Multiple sclerosis MS 
     Total number 
             21 
 
3.13. Immunocytochemistry of olfactory mucosa samples 
Cotton swabs immersed in saline solution were vortexed for 1’ and 400 μL of suspended 
solution was transferred into special tubes. Sample was centrifuged (Cytospin™ 4 
Cytocentrifuge Gain, Thermo Scientific) at 500 × g for 8 minutes at RT to allow the 
deposition of suspended cells onto slides for immunocytochemical analysis. The final 
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preparation was dried and fixed with 4% paraformaldehyde  (4°C overnight). In order to 
block the action of endogenous peroxidases, slides were incubated for 15’ at RT with H2O2 
(6 %) and subsequently washed in ultrapure water (Sigma) 3 times for 5’. To permeabilize 
the cells, slides were coated with PBS + 0.05% Triton X-100 (Sigma-Aldrich) for 10’ and 
then washed with PBS (3 times for 5 minutes). Sections were incubated with 10% goat 
serum (Normal Goat Serum, Dako) diluted in PBS for 30’. Serum was removed and sections 
were incubated with rabbit polyclonal antibody directed against receptors expressed by 
olfactory mucosa neurons (Olfactory marker protein, Abcam) overnight at RT. Samples 
were incubated with a biotinylated anti-rabbit secondary antibody (Vector BA- 2000) for 1 
hour at RT. To increase signal detection, the ABC procedure was performed using the 
Vector commercial kit (VECTASTAIN® Elite® ABC-HRP Kit): slides were incubated for 45’ 
with a solution composed of avidin and biotinylated horseradish peroxidase (HRP) and 
then washed one time in PBS for 5’ and 2 times in distilled water for 5’. Reaction was 
developed with a solution of 0.05% 3-3'-diaminobenzidine (DAB - Vector Labs) containing 
0.02% H2O2 for 2’ and quickly blocked by immersing slides in distilled water. Finally, a 
counterstaining with Carazzi’s hematoxylin was performed for about 30’’. The samples were 
then dehydrated with serial passages in EtOH (from 70% to 100%) of 30-60’’ each and 
immersed in 100% Xylene for 5’ (2 steps). Cover slides were mounted with Eukitt (Bio 
Optica) and observed under an optical microscope (Nikon). 
3.14. Extraction of exosomes from urine 
Urine was collected from patients with a clinical diagnosis of Alzheimer’s disease (AD), 
Frontotemporal dementia (FTD), Progressive supranuclear palsy (PSP), Corticobasal 
degeneration (CBD), as described in Table 3.3. Urine from four healthy subjects (HC) were 
also collected and used as controls. Five mL of urine was divided into ten aliquots of 0.5 
mL. Each aliquot was centrifuged at 3’500 × g for 10’ at 4°C to remove cellular debris and 
supernatants were centrifuged twice at 4’500 × g for 10’ at 4°C. Supernatants of all aliquots 
were pooled together and PBS 1X was added to reach a final volume of 10 mL. The sample 
was subjected to ultra-centrifugation at 110’000 × g for 1 hour at 4°C (Beckman TLA 
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120.2). Fifty µL of PBS was used to re-suspend pellet. Samples were analyzed by means of 
Western blot as previously described using monoclonal primary antibody against the 
exosomal marker CD63 (ThermoFisher Scientific) or stored at -80°C for RT-QuIC analysis. 
Table 3.3 List of subjects from which urinary exosomes were collected and analyzed in this study, 
reporting the number of samples and the acronym used. 
Number of 
urine samples 
Clinical diagnosis Acronym 
Primary Tauopathies 
3 Frontotemporal dementia FTD 
1 Progressive supranuclear palsy PSP 
1 Corticobasal degeneration CBD 
Secondary Tauopathies 
8 Alzheimer’s disease AD 
Other conditions 
4 Healthy control HC 
Total number 
              17 
3.15. Collection of cerebrospinal fluid samples 
Cerebrospinal fluid (CSF) samples were collected from patients with a clinical diagnosis of 
Alzheimer’s disease (AD) and from Non-demented patients (NDP) by lumbar puncture 
following a standard procedure. After collection, CSF was centrifuged at 1’000 × g for 10’ 
and stored in polypropylene tubes at −80 °C until RT-QuIC analysis. The number of CSF 
samples for each condition and the acronym used in this study were summarized in Table 
3.4. 
Table 3.4 List of patients from which CSF was collected and analyzed in this study, reporting the number 
of samples for each condition and the acronym used. 
Number of 
CSF samples 
Clinical diagnosis Acronym 
Secondary Tauopathy 
8 Alzheimer’s disease AD 
Other conditions 
8 Non-demented patient NDP 
Total number 
              16 
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3.16. RT-QuIC analysis of tauK18, αS, tauK19, Aβ1-4o and Aβ1-42 PFFs and brain 
homogenates 
The solution containing tauK18 PFFs was sonicated 3 times for 1’ at 200 W and serially 
diluted (from 10-1 to 10-14 volume/volume) in its own reaction buffer. Five µL of pure or 
diluted tauK18 PFFs (10-2, 10-4, 10-6, 10-8, 10-10, 10-12, 10-14) was added to 95 µL of reaction 
mix. In the cross-seeding experiment, five µL of each solution containing tauK18, αS, 
tauK19, Aβ1-40 or Aβ1-42 PFFs was added to 95 µL of reaction mix. Brain homogenates (BHs) 
from neuropathologically confirmed cases of FTDP-17, PSP, AD, DLB, and NDP were 
prepared as previously described (Paragraph 3.6) and diluted from 10-1 to 10-6 in 1X PBS. 
Two µL of pure or diluted BH (10-2, 10-4 and 10-6) was added to 98 µL of reaction mix.  
Condition #5, among the previously described in Paragraph 3.1, was chosen for evaluating 
tauK18 RT-QuIC seeding abilities of (i) tauK18 PFFs, (ii) FTDP-17, PSP, AD, DLB, and NDP 
BHs and (iii) αS, tauK19, Aβ1-40 or Aβ1-42 PFFs, with some modifications. In particular, all 
reagents used for the preparation of the reaction mix were filtered through a 0.22 µm filter 
and all RT-QuIC reactions were performed in triplicate. The average fluorescence intensity 
of the three replicates was calculated and resulting values were plotted in a graph against 
time together with standard error from the mean (±SEM). 
3.17. RT-QuIC analysis of OM, urinary exosomes and CSF samples 
Different amount of OM (2, 5 or 10 µL of pure or diluted 1:10 and 1:50 volume/volume 
samples), CSF (5 or 10 µL) and urinary exosomes (5 µL) samples was added to RT-QuIC 
reaction mix reaching a final volume of 100 µL in each well. RT-QuIC reaction mix was 
prepared as previously described (condition #5, Paragraph 3.1), with some modifications: 
tauK18 concentration was initially used as in condition #5 and then increased to 20 μM. 
Reactions with OM samples were incubated at 37°C, whereas CSF and urine exosomes 
were incubated at 35°C. A sample was considered “capable of seeding tauK18 
aggregation” if at least 2 out 3 replicates induced the aggregation of tauK18 in RT-QuIC. 
The average fluorescence intensity of the two or three replicates capable of seeding 
activity was calculated and plotted against time together with the standard error of the 
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mean (±SEM). If only one (or none) of the replicates triggered tauK18 aggregation, we 
considered the sample as “incapable of seeding tauK18 aggregation” and the average 
fluorescence intensity of replicates that do not display fluorescence increasing was 
calculated (±SEM). Additionally, a threshold settled at 10’000 AU of fluorescence intensity 
and at 10 hours from the beginning of reaction was applied in the analysis of urinary 
exosomes and CSF samples to distinguish samples characterized by a higher seeding 
activity from those who triggered tauK18 aggregation with less efficiency. Samples who 
induced tauK18 aggregation before this threshold were considered as “positive”, whereas 
the other samples were considered as “negative”. 
3.18. Transmission electron microscopy analyses 
Ten µL of samples was dropped onto 200-mesh Formvar-carbon coated nickel grids for 30 
minutes and dried using filter papers. The grids were subsequently stained with 25% 
Uranyl Acetate Replacement (UAR, negative staining, Electron Microscopy Sciences) for 10’. 
After this step, the remaining solution was removed using filter papers and the grids were 
air-dried for 15’ before Transmission Electron Microscopy (TEM) analyses. Images were 
recorded at 120 kV with FEI Tecnai Spirit transmission electron microscope, equipped with 
an Olympus Megaview G2 camera. 
3.19. Fourier transform infrared spectroscopy 
Fourier-transform infrared (FTIR) spectroscopy was performed in attenuated total reflection 
(ATR) as previously reported [259]. In particular, 100 µL of final tauK18 RT-QuIC products 
from self-assembly and reactions seeded with tauK18 PFFs or AD, CBD, PSP and PD OM 
were centrifuged at 100’000 × g and the resulting pellet was re-suspended in 20 µL of 1X 
PBS. Two  µL of sample aliquots were deposited on the single reflection (ATR-1R) or nine 
reflections (ATR-9R) diamond crystal of the ATR device and the FTIR spectra were collected 
after solvent evaporation. A 670-IR spectrometer (Varian Australia, Mulgrave, Australia) 
equipped with a nitrogen-cooled mercury cadmium telluride detector was used for FTIR 
analysis. The second derivatives of the measured spectra were obtained after Savitsky-
Golay smoothing using the Resolutions-Pro software (Varian Australia).  
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3.20. Atomic force microscopy analysis 
Final tauK18 RT-QuIC reaction products were diluted 1:1 with 10 mM HCL and analyzed by 
Atomic force microscopy (AFM). Briefly, twenty µL was spotted onto freshly cleaved mica 
(Bruker AFM probes) at RT for 5’. Samples were washed with 8 mL of ultrapure water and 
finally dried under gentle nitrogen flow. AFM measurements were carried out on a 
Multimode AFM with a Nanoscope V system operating in tapping mode, using standard 
antimony-doped silicon probes (Bruker AFM probes).  
3.21. Statistical analyses 
Graphpad Prism (v5.0) was used for all statistics and graphic representation of RT-QuIC 
kinetics (GraphPad Software, San Diego, California, USA). TEM images were analyzed with 
Gwyddion software (free software, GNU General Public License) for measuring fibrils length 
and cross-over periodicity. Final values were compared with a double-tailed unpaired t-test 
(Mann-Whitney U test). 
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CHAPTER IV 
4. RESULTS 
4.1. Optimization of tauK18 aggregation protocol in RT-QuIC 
Two different experimental conditions for tauK18 aggregation in RT-QuIC have been 
initially tested, in order to find the best aggregation buffer for tauK18 among the acidic 
PIPES (pH 6.5) and the neutral PBS buffer (pH 7.4). 
An increase in fluorescence values was observed in both conditions within few hours (Fig 
4.1), indicating that we have efficiently set up a protocol for tauK18 aggregation. Notably, 
by the use of acidic PIPES buffer (Fig 4.1, blue line) the aggregation of the protein was 
extremely rapid, starting within 1 hour from the beginning of the reaction and reaching the 
plateau almost immediately. In contrast, tauK18 self-assembly in PBS buffer (Fig 4.1, rede 
line) displayed the typical sigmoidal kinetics of amyloid formation, showing a lag phase of 
5 hours and reaching the plateau after 20-25 hours, thus indicating that PBS might be a 
suitable buffer for our aggregation studies. 
 
Figure 4.1  Comparison of tauK18 self-assembly in RT-QuIC using PIPES or PBS buffer. 
tauK18 self-assembly in RT-QuIC using the acidic PIPES buffer (blue line) was extremely rapid, as 
measured by the increase in fluorescence values (AU), and its aggregation kinetics reached the plateau 
within 1 hour from the beginning of the reaction. Fibrillization of tauK18 using the neutral PBS buffer (red 
line) displayed the typical sigmoidal curve with a lag phase of 5 hours and a plateau phase reached at 
20-25 hours. 
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The presence of amyloid fibrils in final RT-QuIC products of tauK18 self-assembly in PBS 
buffer (Fig. 4.1, red line) was then assessed by collecting samples at the end of the reaction 
and performing TEM analysis and staining with amyloid-specific dyes, such as Congo Red, 
ThT and ThS. 
 
Figure 4.2  Characterization of final RT-QuIC products of tauK18 self-assembly in PBS buffer. 
A) TEM analysis of final RT-QuIC products of tauK18 self-assembly in PBS buffer showed the presence of 
an intricate tangle of amyloid fibrils. Some pair twisted protofilaments were also observed (red arrow); B) 
ThS and ThT staining of final aggregates displayed the presence of β-sheet structures as a strong 
fluorescence signal was detected at approximately 482 nm when samples were excited at 450 nm; C) 
Congo Red staining showed the presence of amyloid-like aggregates characterized by an orange-red 
appearance under light microscopy (⊖) and apple-green birefringence under polarized light (⊕, white 
arrow); B) and C) images were acquired at 40X of magnification . 
 
As showed in Fig. 4.2A, TEM analysis displayed the presence of well-structured fibrils 
forming an intricate tangle. Some fibrils were found to be composed of two twisted 
protofilaments (Fig. 4.2A, red arrow) and resembled the disposition acquired by tau fibrils 
in Paired Helical Filaments (PHFs) observed in AD brains.  
Similarly, ThS and ThT dyes positively stained aggregates characterized by a strong green 
fluorescence signal (Fig. 4.2B), indicating the presence of β-sheet structures. Congo Red 
staining confirmed the presence of amyloid aggregates with typical apple-green 
birefringence under polarized light (Fig.4.2C, ⊕) that disappears with un-polarized light 
(Fig.4.2C, ⊖). Therefore, we decide to perform our tauK18 aggregation studies by using 
PBS buffer and we collected final RT-QuIC products of the reaction, named tauK18 
preformed fibrils (tauK18 PFFs),  for seeding studies. 
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In order to slow down tauK18 self-assembly to eventually observe an acceleration of its 
aggregation kinetics in seeding assays, a set of experimental conditions were tested. In 
particular, (i) we decreased the concentration of the protein (from 8 µM to 4 μM), (ii) we 
excluded DTT from the reaction mix and (iii) we prolonged the incubation time, thus 
reducing the total number of shakings. Combination of these modifications resulted in four 
reaction mixes (see Materials and methods for details, paragraph 3.1) that were subjected 
to cycles of 1’ shaking and 1’ incubation (Fig 4.3A, named #1, #2, #3, #4) or to cycles of 1’ 
shaking and 14’ incubation (Fig 4.3B, named #5, #6, #7, #8) in RT-QuIC.  
 
Figure 4.3 Evaluation of tauK18 self-assembly in RT-QuIC under different experimental settings. 
Four tauK18 reaction mixes were subjected to A) cycles of 1’ shaking and 1’ incubation, showing in all 
conditions a rapid aggregation of the protein as indicated by increase in fluorescence at 4 (#1 and #4),  
5 (#3) and 7 hours (#2) from the beginning of the reaction; B) 1’ shaking and 14’ incubation, displaying a 
slower aggregation kinetics in all conditions characterized by no (#7 and #8) or very little (#5 and #6) 
increase in fluorescence values after 20 hours. 
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We observed that, despite the biochemical condition used, the extension of incubation 
time from 1’ to 14’ (Fig. 4.3B) almost abolished tauK18 self-assembly as indicated by no (#7 
and #8, orange and green lines) or very little increase in fluorescence values after 
approximately 20 hours (#5 and #6, red and purple lines). In contrast, cycles of 1’ shaking 
and 1’ incubation (Fig. 4.3A) induced a very rapid aggregation of the protein as indicated 
by increase in fluorescence at 4 (#1 and #4, red and green lines),  5 (#3, orange line) and 7 
hours (#2, purple line) from the beginning of the reaction. 
Given that we need a slow self-assembly kinetics to perform seeding experiments, cycles of 
1’ shaking and 14’ incubations (Fig. 4.3B) were chosen as experimental setting for our 
tauK18 seeding assays in RT-QuIC.  
4.2. Evaluation of PFFs seeding activity for tauK18 in RT-QuIC 
We evaluated the ability of tauK18 PFFs to promote or accelerate tauK18 aggregation 
kinetics in RT-QuIC when added at the beginning of the reaction in conditions #5, #6, #7 
and #8. To this aim, 10 μL or 5 μL of tauK18 PFFs (which were estimated to contain 
aggregates in the range of micrograms and nanograms, respectively) were added to four 
new reaction mixes and their aggregation kinetics were compared to the self-assembly of 
tauK18 (Fig. 4.4).  
Results showed a strong increase in fluorescence within few hours after the addition of 
tauK18 PFFs (both nanograms and micrograms) in all experimental conditions indicating a 
strong seeding ability of PFFs in our RT-QuIC assay (Fig. 4.4). 
In particular, in condition #5, tauK18 PFFs showed the highest seeding efficiency, reaching 
the plateau within 1 and 3 hours from the beginning of the assay (Fig. 4.4, red and light red 
lines). In conditions #6, #7 and #8, the plateau was reached between 5 and 10 hours (Fig. 
4.4, orange, purple and green lines). Notably, in condition #8 kinetics of seeded samples 
reached fluorescence values between 30’000 and 40’000 AU (Fig. 4.4, green and light green 
lines), which were lower if compared to the other conditions, characterized by fluorescence 
values above 60’000 AU (Fig. 4.4, red, orange and purple lines).  
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Figure 4.4 Evaluation of tauK18 PFFs seeding assay in RT-QuIC under different experimental conditions 
A-D) tauK18 aggregation was induced almost instantly by the addition of micrograms or nanograms of 
tauK18 PFFs (colored lines) in all conditions, whereas no aggregation or very little increase in 
fluorescence values was observed in self-assembly reactions (black dotted line). However, the 
aggregation kinetics in seeded reactions displayed some differences among the condition tested: A) in 
condition #5, seeded reactions (red an light red lines) reached the plateau within 1 and 3 hours; B, C, 
and D) in condition #6, #7 and #8, tauK18 aggregation kinetics (orange, purple and green lines) reached 
the plateau phase between 5 and 10 hours; D) in condition #8, tauK18 aggregation kinetics reached 
lower fluorescence levels at the plateau (between 30’000 and 40’000 AU) if compared to the other 
conditions (above 60’000 AU).  
 
Given that in condition #5 tauK18 PFFs showed the highest seeding efficiency, this 
experimental setting was chosen for our tauK18 seeding assays in RT-QuIC.  
In particular, we evaluated whether the addition of lower amounts of PFFs was still able to 
promote tauK18 aggregation and whether this acceleration might show a dose-dependent 
response. To this aim, tauK18 PFFs were serially diluted, ranging from nanograms to 
attograms,  and each dilution was added in triplicate to a new reaction mix in RT-QuIC. 
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Figure 4.5 Evaluation of the seeding activity of different amounts of tauK18 PFFs in RT-QuIC. 
tauK18 aggregation kinetics in RT-QuIC was accelerated by the addition of all the amounts of PFFs tested 
(colored lines), whose mass was estimated to be in the range of nanograms (brown and dark red lines) 
to attograms (pink and light pink lines). tauK18 PFFs seeding activity was almost proportional to the 
amount of seeds added, as indicated by the proportional decrease in lag phases if compared to the self-
assembly of the protein (black dotted line). Reactions were performed in triplicate and the average 
fluorescence intensities were plotted against time (±SEM). 
 
As shown in Fig. 4.5, all PFFs dilutions (colored lines) efficiently accelerated tauK18 
aggregation in RT-QuIC if compared to the self-assembly of the protein (black dotted line), 
indicating that attograms of tauK18 PFFs were still capable of seeding activity in our assay 
(pink and light pink lines). 
Interestingly, the seeding effect was almost proportional to the amount of seeds added. 
Indeed, the addition of 500 ng of PFFs instantly induced the aggregation of tauK18 (brown 
line), whereas tauK18 fibrillization in the presence of 50 ng and 500 pg of PFFs displayed a 
lag phase of 5 hours (dark red line) and 15 hours (red line), respectively. Similarly, the 
addition of 5 pg, 500 fg and 5 fg of PFFs induced the aggregation of tauK18 at 17, 18 and 
19 hours from the beginning of the reaction, respectively (light red lines). Conversely, 
samples seeded by 500 ag and 5 ag of PFFs (pink and light pink lines) were characterized 
by a shorter lag phase (10 and 16 hours) if compared to the seeding activity of higher 
amounts of seeds.  
Therefore, with our experimental setting, we were able to observe an acceleration of 
tauK18 aggregation kinetics after the addition of attograms of tauK18 PFFs in RT-QuIC.  
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4.3. RT-QuIC analysis of brain homogenates collected from patients with 
primary and secondary tauopathies 
Considering the high level of RT-QuIC sensitivity, we decided to verify its ability to detect 
pathological tau aggregates present in neuropathologically confirmed brain samples of 
patients with AD, FTDP-17, and PSP. Brains from a Non-demented patient (NDP) and from 
a neuropathologically confirmed case of DLB were used as controls. 
Firstly, we evaluated the presence of insoluble tau associated with the presence of PHFs in 
those brains, named PHF-tau. Brain samples were homogenized and subjected to serial 
steps of high-speed centrifugation in order to isolate insoluble PHF-tau aggregates. 
Western blot analyses confirmed the presence of insoluble PHF-tau only in brain 
homogenates of patients with AD, PSP, and FTDP-17 (Fig. 4.6A). Indeed, as previously 
described in Paragraph 1.2, Western blot of PHF-tau showed the presence of the typical 
AD-triplet at 60, 64 and 69 kDa (tau60, 64 and 69) in AD brain and the typical PSP-doublet 
at 60 and 64 kDa (tau60, 64) in the PSP case. Moreover, the same tau doublet (tau60, 64) 
was detected in the FTDP-17 brain, which is in line with insoluble tau usually found in cases 
associated with P301L tau mutation. No insoluble PHF-tau was detected in DLB and NDP 
brains (Fig. 4.6A). 
Preliminary TEM analysis also showed the presence of fibrils in PHF-tau extracted from AD, 
PSP and FTDP-17 brains, which seemed to be characterized by different sizes and 
morphologies (Fig.4.6B). Additionally, conformational stability assay showed that PHF-tau 
extracts from AD and FTDP-17 cases possessed an overall higher resistant to GdnHCl 
denaturation if compared to PSP samples, thus suggesting the presence of different 
conformations of insoluble PHF-tau in our brain extracts (Fig. 4.6C).  
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Figure 4.6 Characterization of PHF-tau extracts from FTDP-17, PSP and AD brains. 
A) The presence of insoluble PHF-tau in brains of patients with tauopathies were confirmed by Western 
blot analysis using PHF-6 antibody, showing the typical tau doublet in FTDP-17 and PSP (migrating at 60 
and 64 kDa) and the typical tau triplet (at 60, 64 and 69 kDa) in the AD sample. B) TEM analysis of PHF-
tau extracts revealed the presence of fibrils in PHF-tau extracted from FTDP-17, PSP and AD samples. C) 
Western blot and densitometric analysis of the conformational stability assay of insoluble PHF-tau 
showed that FTDP-17 and AD extracts possess an overall higher resistance to denaturation if compared 
to PSP. Dashed lines indicate cropped images from distant samples in the same gel.  
 
Therefore, the same brain homogenates (BH) were analyzed by means of RT-QuIC to 
evaluate their ability to induce tauK18 aggregation. As shown in Fig. 4.7A, brain samples 
from AD (brown line), PSP (orange line) and FTDP-17 (pink line) cases efficiently 
accelerated tauK18 aggregation kinetics in RT-QuIC. NDP BH (green line) also induced a 
slight increase in tauK18 aggregation, however, its seeding activity was less efficient if 
compared to tauopathies samples. Interestingly, DLB sample seemed to delay tauK18 
aggregation (blue line). 
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Figure 4.7 RT-QuIC analysis of brain homogenates from patients with definite diagnosis of primary and 
secondary tauopathies, compared to non-tauopathies cases. 
A) tauK18 aggregation was efficiently induced in RT-QuIC by the addition of BH from 
neuropathologically confirmed cases of AD, PSP and FTDP-17: AD BH sample (brown line) triggered the 
aggregation almost immediately, whereas PSP (orange line) and FTDP-17 (pink line) BH samples were 
characterized by a lag phase of 12 and 14 hours, respectively. A slight aggregation of the protein was 
observed after the addition of NPD BH (green line), whereas no increase in fluorescence was detected in 
the DLB BH sample (blue line).  B) Comparison between aggregation kinetics of tauopathies (red line) 
and non-tauopathies (navy blue line) BH samples, showing that tauopathies were the most efficient in 
triggering tauK18 aggregation in RT-QuIC. Reactions were performed in triplicate and the average 
fluorescence intensities were plotted against time (±SEM). 
 
By analyzing aggregation kinetics of tauopathies and comparing them with non-
tauopathies samples (Fig. 4.7B), it is clearly visible that tauopathies (red line) triggered the 
aggregation of tauK18 with higher efficiency if compared to the others BH (Fig. 4.7B, navy 
blue line).  
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Thus, our tauK18 RT-QuIC assay was able to detect tau seeding activity in brain 
homogenates collected from patients with primary and secondary tauopathies.  
Additionally, we evaluated the ability of our assay in detecting pathological tau aggregates 
present in serial dilutions of brain samples to assess its sensitivity. 
Similar results were obtained by adding BHs diluted at 10-2 (volume/volume), even if the 
efficiency of tauopathies in triggering tauK18 aggregation was less evident. Indeed, all 
samples induced tauK18 aggregation (Fig. 4.8A), with FTDP-17 and PSP samples reaching 
significantly higher fluorescence values. However, AD BH even delayed tauK18 
aggregation. When fluorescence intensities of tauopathies samples were pooled together 
(Fig. 4.8B), we still observed differences in tauK18 aggregation kinetics between 
tauopathies and non-tauopathy samples (NDP and DLB), thus allowing us to distinguish 
between these conditions. 
Conversely, when we tested higher dilutions of BH samples, these differences were no 
more visible. Indeed, all BH samples diluted at 10-4 and 10-6 displayed the same seeding 
activity on tauK18 aggregation and all kinetics were comparable in time and in 
fluorescence values reached (Fig. 4.8C and E). The lack of differences was clearly visible also 
by pooling together all tauopathies and comparing them to non-tauopathy samples (Fig. 
4.8D and F). 
4.4. RT-QuIC analysis of OM collected from patients with tauopathies 
Given that our tauK18 RT-QuIC assay was able to detect tau seeding activity in brain 
homogenates collected from patients with definite diagnosis of primary and secondary 
tauopathies, we decide to evaluate seeding activity of olfactory mucosa (OM) samples from 
patients with a clinical diagnosis of AD, PSP, CBD and FTDP-17 and to compare them to 
OM samples from patients with clinical diagnosis of synucleinopathies (PD, DLB and MSA) 
and Multiple sclerosis (MS).  
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Figure 4.8 RT-QuIC analysis of serial dilutions of brain homogenates from patients with definite diagnosis 
of primary and secondary tauopathies, compared to non-tauopathies cases.   
A) BH collected from patients with tauopathies and diluted at 10-2 (volume/volume) were less efficient 
than pure BH in seeding tauK18 aggregation, however B) they reached higher fluoresce levels if 
compared to non-tauopathy cases. C) and E) all BH samples diluted at 10-4 and 10-6 displayed the same 
seeding activity on tauK18 aggregation in RT-QuIC, as indicated by pooling aggregation kinetics of 
tauopathies samples and comparing them to non-tauopathy cases (D and F). Reactions were performed 
in triplicate and the average fluorescence intensities were plotted against time (±SEM). 
 
OM were collected with a non-invasive procedure, called nasal brushing, depicted in Fig. 
4.9A. First of all, we assessed the presence of olfactory neurons in OM samples by 
depositing collected cells (Fig. 4.9B) on microscope glass slides. Immunocytochemistry 
revealed the presence of olfactory neurons (red arrow, Fig. 4.9C), which were 
immunoreactive to olfactory marker protein antibody and were characterized by the 
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presence of spheroidal soma and long axons. Supporting cells (Fig. 4.9C) were also visible 
as they were characterized by an ellipsoidal nucleus, elongated soma, and numerous thin 
microvilli.  
 
Figure 4.9 Collection and immunocytochemistry of olfactory mucosa (OM) samples. 
A) OM can be obtained by a non-invasive procedure, known as nasal brushing, in which a cotton swab 
was rubbed against the medial turbinate of the nasal cavity. B) OM cells were released from the cotton 
swab by vortexing and were precipitated by centrifugation. C) The presence of olfactory receptor 
neurons (red arrow) and supporting cells was confirmed by hematoxylin staining and 
immunocytochemistry using the olfactory marker protein antibody. 
 
In a preliminary experiment, different volumes of OM samples collected from patients with 
a clinical diagnosis of FTDP-17 (n=2), PSP (n=1), CBD (n=1) and AD (n=3) were tested in 
order to find the best experimental setting for our OM RT-QuIC assay. As shown in Fig. 
4.10, few OM displayed seeding activity on tauK18 aggregation. In particular, by adding 2 
μL of OM, tauK18 aggregation was slightly induced only by AD OM#3 sample (brown line) 
after 80 hours from the beginning of the reaction. 
The addition of 5  μL of OM efficiently triggered tauK18 aggregation in one CBD sample 
(OM#1, purple line), reaching fluorescence values above 7’000 AU. No seeding activity has 
been observed in any of the reaction mixes supplemented with 10 μL of OM. Thus, we 
considered 5 μL of OM as a suitable volume for our tauK18 RT-QuIC assay.  
 
A B C 
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Figure 4.10 Optimization of RT-QuIC analysis of OM samples, evaluating the effect exerted by the 
addition of different volumes of OM collected from patients with clinical diagnosis of primary and 
secondary tauopathies. 
A) The addition of 2 μL of OM samples from patients with CBD (OM#1, purple line), PSP (OM#1 dark 
orange line), FTDP-17 (OM#1 and OM#2, pink and light pink lines) and AD (OM#1, OM#2 and OM#3, 
red, dark red and brown lines) did not efficiently induce tauK18 aggregation, as only a slight increase in 
fluorescence was observed in the AD OM#3 sample (brown line) after 80 hours from the beginning of 
the reaction. B)  tauK18 aggregation was significantly induced by the addition of 5 μL of OM collected 
from one CBD case (OM#1, purple line), whereas no seeding activity has been observed in the other 
samples. C)  No increase in fluorescence was detected after the addition of 10 μL of OM collected from 
CBD, PSP, FTDP-17, and AD cases. Reactions were performed in triplicate and the average fluorescence 
intensities were plotted against time (±SEM). 
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Given the overall low level of tauK18 aggregation in this preliminary experiment, 
presumably due to the presence of OM components able to interfere with tauK18 
aggregation, we decide to modify the experimental setting in order to increase sensitivity 
and specificity of our RT-QuIC assay: (i) we increased tauK18 concentration to 20 μM to 
provide an higher amount of substrate available for the conversion in RT-QuIC and (ii) we 
diluted OM samples 1:10 to decrease the concentration of OM constituents that might 
interfere with tauK18 aggregation in RT-QuIC.  
With this new experimental setting, we evaluated tauK18 seeding ability of OM samples 
collected from patients with a clinical diagnosis of FTDP-17 (n=2), CBD (n=2), PSP (n=4), 
gAD (PSEN, n=1), AD (n=1), gPD (PARK8, n=2), PD (n=1) and MS (n=2). 
Figure 4.11 RT-QuIC analysis of OM collected from patients with clinical diagnosis of primary and 
secondary tauopathies, compared to synucleinopathies and Multiple sclerosis OM samples. 
The addition of OM collected from 2 CBD (OM#1 and OM#2, purple and light purple lines), PSP OM#1 
(dark orange line) and 1 gPD (OM#1, dark blue line) efficiently triggered tauK18 aggregation in RT-QuIC, 
reaching fluorescence values above 40’000 AU and displaying a lag phase of 30 hours (PSP and gPD) 
and 50 hours (CBD). 3 PSP (OM#2, OM#3 and OM#4, orange, light orange, and dark yellow lines), 1 
gPD (OM#2, blue line) and 1 MS (OM#2, dark green line) samples induced a slight increase in 
fluorescence values (between 10’000 and 15’000 AU). All FTDP-17 (OM#1 and OM#2, pink and light pink 
lines) and AD (gAD and AD, red and light red lines) samples, together with 1 PD (light blue line)  and 1 
MS (OM#1, light green line), were not able to trigger tauK18 aggregation. Reactions were performed in 
triplicate and the average fluorescence intensities were plotted against time (±SEM). 
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Thanks to this new experimental setting, some OM triggered the aggregation of tauK18 
with high efficiency (Fig. 4.11). In particular, 1 PSP (OM#1, dark orange line), 2 CBD (OM#1 
and OM#2, purple and light purple lines) and 1 gPD (OM#1, dark blue line) OM induced 
tauK18 aggregation reaching fluorescence intensities above 40’000 AU. Some OM samples, 
such as 3 PSP (OM#2, OM#3 and OM#4, orange, light orange and dark yellow lines), 1 gPD 
(OM#1, blue line) and 1 MS (OM#2, dark green line), were less efficient in triggering 
tauK18 aggregation and induced a slight increase in fluorescence values (between 10’000 
and 15’000 AU). Among OM samples that triggered the aggregation, one group (3 PSP, 2 
gPD, 1 PD and 1 MS) displayed seeding activity between 20 and 30 hours from the 
beginning of the reaction, whereas a second group composed by 2 CBD samples seeded 
the aggregation after 50 hours. Conversely, all FTDP-17 (OM#1 and OM#2, pink and light 
pink lines) and AD (AD OM#1 and gAD OM#1, red and light red lines) OM, together with 1 
PD  (OM#1, light blue line)  and 1 MS (OM#1, light green line), were not able to trigger 
tauK18 aggregation as no increase in fluorescence values was detected in those samples. 
Given the low specificity of our tauK18 RT-QuIC assay, we decide to further dilute OM 
samples from 1:10 to 1:50 (volume/volume) to decrease the amount of OM molecules 
potentially able to influence tauK18 aggregation in RT-QuIC. 
Additionally, we noticed that OM samples from atypical parkinsonisms (PSP, CBD, and PD) 
have shown a greater seeding activity in our experimental conditions if compared to AD 
and FTDP-17 samples. Therefore, we have decided to focus our attention on this group of 
diseases with the aim of recognizing parkinsonian syndromes associated with tau 
pathology and to distinguish them from those associated with α-synuclein (αS) 
accumulation. Thus, we tested OM samples from PSP (n=4), CBD (n=2) and PD (n=2) and 
we included other parkinsonian syndromes, such as MSA (n=2) and DLB (n=2). 
Results are reported in Fig. 4.12 and showed that several OM samples triggered in tauK18 
aggregation in RT-QuIC. 
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Figure 4.12 RT-QuIC analysis of OM collected from patients with clinical diagnosis of atypical 
parkinsonisms and Parkinson’s disease.  
tauK18 aggregation was efficiently induced by 2 CBD (OM#1 and OM#2, purple and light purple lines), 1 
PSP (OM#4, dark yellow line), 1 MSA (OM#1, turquoise line), 2 PD (OM#1 and OM#2, blue and light 
blue lines) and 2 DLB (OM#1 and OM#2, navy blue and light navy blue lines) samples. No seeding 
activity was detected after the addition of 3 PSP (OM#1, OM#2 and OM#3, dark orange, orange, and 
light orange lines) and 1 MSA (OM#2, light turquoise line) samples. Reactions were performed in 
triplicate and the average fluorescence intensities were plotted against time (±SEM). 
 
Indeed, tauK18 aggregation was efficiently induced by OM samples from 2 CBD (OM#1 
and OM#2, purple and light purple lines), 1 PSP (OM#4, dark yellow line), 1 MSA (OM#1, 
turquoise line) 2 PD (OM#1 and OM#2, blue and light blue lines) and 2 DLB (OM#1 and 
OM#2, navy blue and light navy blue lines). An increase in fluorescence values was 
observed almost instantly in samples seeded with DLB and CBD OM. Conversely, no 
seeding activity was detected after the addition of 3 PSP (OM#1, OM#2 and OM#3, dark 
orange, orange, and light orange lines) and 1 MSA (OM#2, light turquoise line) OM, as no 
increase in fluorescence values was observed in those samples. 
In order to improve the sensitivity and specificity of our tauK18 RT-QuIC assay, we decide 
to further decrease the volume of OM seed to reduce cross-seeding activity eventually 
exerted by other protein aggregates (e.g. α-synuclein) or by other molecules present in 
OM samples. 
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Thus, we added 2 μL of OM to a new reaction mix to test the effect of the same OM 
samples on tauK18 aggregation. Results (Fig. 4.13A) showed that tauK18 aggregation was 
triggered unspecifically by OM samples of both synucleinopathies and tauopathies. 
Indeed, tauK18 aggregation was accelerated by 1 CBD (OM#1, purple line), 2 PSP (OM#1 
and OM#3, dark orange and light orange lines), 2 MSA (OM#1 and OM#2, turquoise and 
light turquoise lines) and 2 DLB samples (OM#1 and OM#2, navy blue and light navy blue 
lines). PD OM samples (OM#1 and OM#2, blue and light blue lines)  in this case did not 
display tauK18 seeding activity. Conversely, 1 MSA (OM#2, light turquoise) and 2 DLB OM 
were the most efficient in seeding the reaction (within 10 hours) and fluorescence 
intensities reached the highest values if compared to other samples. 
 
Figure 4.13 RT-QuIC analysis of OM collected from patients with clinical diagnosis of atypical 
parkinsonisms and Parkinson’s disease.  
tauK18 aggregation was efficiently triggered by 1 CBD (OM#2, purple line), 2 PSP (OM#1 and OM#3, 
dark orange and light orange lines), 2 MSA (OM#1 and OM#2, turquoise and light turquoise lines) and 2 
DLB samples (OM#1 and OM#2, navy blue and light navy blue lines). Both PD OM#1 and OM#2 (dark 
blue and blue lines) did not display tauK18 seeding activity. 
 
Indeed, when fluorescence intensities of OM samples collected from tauopathies were 
compared to those of synucleinopathies and PD cases (Fig. 4.14), tauK18 seeding ability 
showed to be higher in atypical parkinonisms associated with αS pathology (navy blue line) 
rather than in those associated with tau (magenta red line).  
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Figure 4.14 Comparison of tauK18 seeding activity in RT-QuIC exerted by OM collected from patients 
with atypical parkinsonisms and Parkinson’s disease.  
tauK18 seeding activity of OM collected from different parkinsonian syndromes showed that samples 
from atypical parkinsonism associated with αS pathology (navy blue line) reached higher fluorescence 
intensities if compared to parkinsonism associated with tau pathology (magenta red line) and Parkinson’s 
disease (PD) (blue line). 
 
4.5. Biochemical and structural characterization of final tauK18 RT-QuIC 
aggregates seeded by OM in RT-QuIC 
Since different OM samples (either from patients with synucleinopathies or tauopathies) 
efficiently induced tauK18 aggregation, we decided to analyze final aggregates with 
biochemical and biophysical techniques with the aim of verifying whether tauK18 might 
have acquired different conformations (presumably driven by different pathological seeds), 
thus allowing us to discriminate between pathologies and to stratify patients with different 
tauopathies.  
Therefore, we collected final tauK18 products seeded by different OM samples from RT-
QuIC assay reported in Fig. 4.11 and we performed preliminary structural investigations by 
Transmission electron microscopy (TEM), Fourier-transform infrared (FTIR) spectroscopy 
and Atomic force microscopy (AFM). 
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First, tauK18 final RT-QuIC aggregates were analyzed by TEM in order to morphologically 
evaluate the size and cross-over periodicity of tauK18 fibrils seeded by different OM 
samples. We analyzed tauK18 aggregates seeded with 1 PSP (Fig. 4.11, OM#1, dark orange 
line), 1 CBD (Fig. 4.11, OM#1, purple line) and 1 gPD (Fig. 4.11, OM#1, dark blue line) OM, 
and 1 AD (Fig. 4.11, OM#1, red line) sample that did not displayed tauK18 seeding activity. 
Images of OM-seeded tauK18 aggregates are reported in Fig. 4.15A and showed the 
presence of an intricate tangle of tauK18 fibrils in CBD and PSP samples, whereas dispersed 
fibrils were observed in the PD sample.  
 
Figure 4.15 TEM analysis of tauK18 aggregates seeded by different OM samples. 
A) RT-QuIC products of tauK18 seeded by different OM samples were analyzed by TEM, showing the 
presence of an intricate tangle of fibrils in CBD and PSP OM#1 samples and some dispersed fibrils in 
gPD OM#1 sample. No fibrils were detected in the AD OM#1 sample. B) tauK18 average fibrils length 
were found to be significantly different among each samples (p-value < 0.0001, ***) and was measured 
as 319.0±7.21 nm (mean±SEM, n=193), 255.5±8.26 nm (mean±SEM, n=161) and 142.2±4.02 nm 
(mean±SEM, n=219) in PSP, CBD and gPD OM samples, respectively. C) tauK18 fibrils cross-over 
periodicity was also found to be significantly different among each condition: PSP OM#1 fibrils showed 
an average cross-over periodicity of 17.46±1.48 nm (mean±SEM, n=10), CBD OM#1 fibrils of 
24.67±1.49 nm (mean±SEM, n=10) and gPD OM#1 fibrils of 11.05±0.58 nm (mean±SEM, n=10). P-value 
of CBD vs PSP was 0.0031 (**), whereas PD vs PSP displayed a p-value of 0.0008 and PD vs CBD a p-
value < 0.0001. B) and C) Statistical analysis was performed with a double-tailed unpaired t-test (Mann-
Whitney U test). 
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No fibrils were observed in the AD OM sample confirming that it did not induce tauK18 
aggregation.  
Fibrils length and cross-over periodicity were also evaluated (Fig. 4.15B), showing that 
gPD-seeded tauK18 fibrils possess the lowest average fibril length, estimated to be around 
142.2±4.02 nm (mean±SEM, n=219), and the smallest cross-over periodicity, around 
11.05±0.58 nm (mean±SEM, n=10). PSP-seeded tauK18 fibrils are characterized by an 
average length of 319.0±7.21 nm (mean±SEM, n=193) and a cross-over periodicity of 
17.46±1.48 nm (mean±SEM, n=10), whereas CBD sample displayed fibrils with 255.5±8.26 
nm (mean±SEM, n=161) of average length and 24.67±1,49 nm (mean±SEM, n=10) of 
cross-over periodicity. These differences were statistically significant, possibly indicating 
that tauK18 conformation might be differently driven by distinct OM seeds. 
The same samples were also analyzed by FTIR to gain structural information regarding the 
secondary structure of tauK18 seeded by different OM samples in RT-QuIC. Fibrils 
generated by tauK18 self-assembly or seeded by tauK18 PFFs were included in the analysis.  
tauK18 aggregates were precipitated by ultra-centrifugation, to exclude the monomeric 
native protein from the analysis and to avoid the presence of salts able to interfere with 
FTIR measurements, and subjected to Attenuated Total Reflection (ATR) analysis in FTIR 
characterized by a single or multiple reflections (1R or 9R, respectively).  
The results of measurements in ATR-1R are shown in Fig. 4.16A, where the absorption 
spectra are listed in the region of the Amide I (1700-1600 cm-1) and Amide II bands (1600-
1500 cm-1) associated with the absorption of the peptide bond. Amid I, in particular, is the 
most sensitive to protein secondary structures. The absorption spectra of PSP (red line) and 
CBD (yellow line) OM-seeded tauK18 showed a very evident band in the spectral region of 
β-sheet structures (1620-1640 cm-1) , whereas the spectra of the other samples was more 
centered in the region around 1652 cm-1, assignable to random coil structures with a 
possible contribution of α-helices. This could indicate that a part of the protein has 
remained disordered.  
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Figure 4.16 FTIR-ATR 1R analysis of tauK18 aggregates seeded by different OM samples. 
A) Absorption spectra in the region 1800-1480 cm-1 of tauK18 final aggregates seeded by OM samples 
in RT-QuIC showed that PSP (red line) and CBD (yellow line) samples possessed a very evident band in 
the spectral region of β-sheet structures, whereas the spectra of the other samples showed a peak in the 
region of random coil structures. B) Samples were re-precipitated to further purify aggregates and re-
analyzed, thus allowing the identification of peaks corresponding to β-sheet structures in tauK18 self-
assembly (gray line) and PFFs-seeded (green line) samples. No β-sheet structures were identified in AD 
(black line) and gPD (blue line) OM samples. C) Zoom in the Amide I region of absorbance spectra 
obtained in B) was used to better visualize the spectral region of β-sheet structures and confirmed results 
showed in B). D) The second derivative of the absorption spectra reported in C) showed that tauK18 self-
assembly and PFFs-seeded samples may possess a higher content of β-sheets if compared to the other 
samples analyzed. 
 
The signal of tauK18 sample seeded by AD OM (black line) was not analyzable in these 
conditions, thus samples were re-precipitated to further purify aggregates and re-analyzed. 
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The results are reported in Fig. 4.16B and 4.16C, where this additional purification step 
allowed us to identify peaks corresponding to β-sheet structures also in tauK18 self-
assembly (gray line) and PFFs-seeded samples (green line). No β-sheet structures were still 
identified in AD and gPD (blue line) OM samples. Second derivative of the absorption 
spectra obtained in Fig. 4.16B allowed us to identify high peaks at 1629 cm-1 in tauK18 self-
assembly (gray line) and PFFs-seeded samples (Fig. 4.16D), thus suggesting that these 
samples might possess a higher content of β-sheets if compared to the other samples.  
Given that the signal obtained with ATR-1R FTIR analysis was not satisfactory, probably due 
to the low amount of tauK18 used as substrate in our experiments, samples were re-
analyzed with a 9-reflective ATR accessory (ATR-9R) and results are shown in Fig. 4.17. The 
first analysis (Fig.17A) showed that PSP (red line) and CBD (yellow line) OM-seeded tauK18 
possessed a very evident band in the spectral region of β-sheet structures, similar to what 
observed with ATR-1R FTIR. However, after the purification step, the highest sensitivity of 
the ATR-9R allowed to better identify β-sheet structures in all tauK18 samples except for 
the sample seeded by AD OM (Fig. 4.17B).  
This evidence was confirmed by the second derivative analysis shown in Figure 4.17C: 
tauK18 self-assembly and PFFs-seeded samples displayed the highest content in β-sheets, 
whereas tauK18 seeded by PSP, CBD, and gPD OM also possess β-sheets structures but in 
lower amount. tauK18 seeded by AD OM showed a predominant random coil structure, 
with the possible contribution of α-helices. 
Incidentally, the analysis of the region around 1740 cm-1 indicates that samples with OM 
seeds might contain lipids, as they present peaks in the region corresponding to C=O 
binding of lipid esters. Interestingly, AD OM sample displayed a very high peak in this 
region, thus suggesting a potential higher content of lipids if compared to other OM 
samples. 
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Figure 4.17 FTIR-ATR 9R analysis of tauK18 aggregates seeded with different OM samples. 
A) Absorption spectra in the region 1800-1480 cm-1 of tauK18 final aggregates seeded by OM samples 
in RT-QuIC were obtained with FTIR-ATR 9R and showed similar results of ATR1R analyses, as also in this 
case PSP (red line) and CBD (yellow line) samples possessed a very evident band in the spectral region of 
β-sheet structures, whereas other samples were characterized by random coil structures. B) The second 
analysis of purified samples showed the presence of β-sheet structures in all samples with the exception 
of AD (black line). By contrast, AD sample was characterized by a high peak in the region of lipid esters. 
C) The second derivative of the absorption spectra reported in B) showed that tauK18 self-assembly and 
PFFs-seeded samples may possess a higher content of β-sheets if compared to the other samples 
analyzed. 
 
Another preliminary structural study was conducted by analyzing OM-seeded tauK18 
aggregates with AFM with the aim of discriminating between different tauopathies. Indeed, 
final tauK18 RT-QuIC products seeded by PSP OM#1, CBD OM#1, and AD OM#1 were 
adsorbed onto the mica surface and subjected to AFM analysis. The results are reported in 
Fig. 4.18, in which PSP OM-seeded tauK18 aggregates showed the presence of around 1 
μm long fibrils dispersed among thin and presumably fragmented fibrils, whereas thin 
CBD-OM seeded sample present only few long fibrils and less fragmented filaments. No 
fibrils were detected in tauK18 sample seeded by AD, indicating that no protein 
aggregation occurred.  
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Figure 4.18 AFM analysis of final tauK18 aggregates seeded with different OM samples. 
AFM analysis of final tauK18 RT-QuIC products seeded by PSP OM#1, CBD OM#1, and AD OM#1 
showed the presence of long fibrils (around 1 μm, white arrowS) and a large amount of thin, presumably 
fragmented, filaments in the PSP sample, whereas CBD sample present only few long fibrils (white 
arrowS) and less fragmented filaments. No fibrils were detected in tauK18 sample seeded by AD, 
indicating that no protein aggregation occurred. 
 
Given that tauK18 fibrils seeded by different OM samples displayed some morphological 
differences in our preliminary structural studies, we also collected final tauK18 RT-QuIC 
reaction products from the experiment reported in Fig. 4.13 and we performed a 
proteolytic digestion with Proteinase K (PK) to evaluate if tauK18 might have acquired 
different conformations when seeded by distinct OM samples, thus displaying different 
levels of PK-resistance. 
First, monomeric tauK18, RT-QuIC products of tauK18 self-assembly and PFFs-seeded 
reactions were collected and evaluated by Western blot analysis (Fig. 4.19A). Monomeric 
tauK18 sample showed the presence of a single band at 13.8 kDa corresponding to tauK18 
monomers. tauK18 self-assembly and PFFs-seeded samples were characterized by an 
analogous band corresponding to monomeric tauK18 which have been not assembled into 
fibrils and by bands with higher MW presumably corresponding to dimers, trimers, 
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oligomers, and larger tauK18 aggregates. Secondly, we treated samples with different 
concentrations of PK. 
We observed that, by treating samples with 20 μg/mL of PK for 30’, monomeric tauK18 and 
aggregates generated by the self-assembly of the protein were completely digested, 
whereas PFFs seeded sample displayed a higher degree of PK-resistance which led to the 
formation of bands with a MW ranging from 6 to 62 KDa (Fig. 4.19B). According to these 
results, we decided to subject tauK18 final RT-QuIC products seeded by different OM 
samples to the same PK treatment. Conversely, all samples were completely digested (Fig. 
4.19C), thus indicating that OM seeding has produced tauK18 fibrils less resistant to 
proteolysis digestion if compared to tauK18 PFFs and, more important, no differences in 
PK-resistance were observed among OM samples subjected to this proteolytic treatment.  
 
Figure 4.19 Biochemical analysis of tauK18 aggregates seeded by different OM samples.   
A) Western blot of monomeric, self-assembled and PFFs-seeded tauK18 RT-QuIC products, showing the 
presence of a single band at 13.8 kDa corresponding to tauK18 monomers and bands with higher MW 
corresponding to dimers, trimers, and oligomers in RT-QuIC products of both self-assembly and PFFs-
seeded reactions. B) PK treatment completely digested both monomeric and self-assembled tauK18, 
whereas RT-QuIC products of PFFs-seeded reaction were partially resistant to this treatment (red arrow). 
C) Absence of PK resistant bands in PK-treated tauK18 aggregates seeded by different OM samples. 
Blots were immunostained with the RD4 antibody. Asterisk indicates antibody cross-reaction with PK. 
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4.6. RT-QuIC analysis of urinary exosomes collected from patients with 
primary and secondary tauopathies 
Given the overall low level of sensitivity and specificity of our tauK18 RT-QuIC assay in 
detecting tau seeding activity in OM of patients with tauopathies, we decided to analyze 
other peripheral body fluids, such as urine. Urine is a sample very easy to collect, however, 
it contains several metabolic products that might alter tauK18 RT-QuIC assay. Thus, we 
decide to purify urinary exosomes and to assess their effect on tauK18 aggregation. 
First, we established a protocol to efficiently isolate exosomes from 5 mL of urine by steps 
of centrifugation at high speed. As shown in Fig. 4.20, the presence of exosomes was 
confirmed by means of Western Blot using an antibody directed against the exosomal 
marker CD63 (Fig. 4.20A). Moreover, TEM analysis of urine extracts showed the presence of 
vesicles characterized by a diameter comprised between 40 and 100 nm, in line with the 
putative size of exosomes (Fig. 4.20B).  
 
Figure. 4.19 Biochemical and TEM analysis of urinary exosomes extracts. 
A) Western blot analysis of urine extracts showed the presence of a large band between 30 and 60 kDa 
corresponding to the exosomal marker CD63. B) TEM images of urine extracts showed the presence of 
vesicles with a diameter ranging from 40 to 100 nm, in line with the putative size of exosomes. 
 
Exosomes were isolated from patients with a clinical diagnosis of FTD (n=3), PSP (n=1), 
CBD (n=1), AD (n=8) and from healthy controls (HC, n=4) and analyzed by means of RT-
QuIC. The results are reported in Fig. 4.20A, indicating that exosome isolations from all 
tauopathies triggered tauK18 aggregation. The majority of these samples displayed an 
efficient seeding activity, characterized by a lag phase of 5-10 hours. Conversely, one HC 
A B 
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sample (EXO#2, dark olive green line) induced the aggregation of tauK18 within 10 hours 
from the beginning of the reaction, similarly to tauopathies samples. One PSP (EXO#1, 
orange line) and two HC (EXO#1 and EXO#4, olive green and dark green lines) sample 
seeded tauK18 aggregation with less efficiency (after 10 hours). One HC exosome 
preparation (EXO#3, light green line) did not display tauK18 seeding activity. These 
observations suggested us to apply a threshold settled at 10’000 AU of fluorescence 
intensity and at 10 hours from the beginning of reaction, to distinguish samples 
characterized by a higher seeding activity from those who triggered tauK18 aggregation 
with less efficiency (Fig. 4.20A, black dotted lines). Samples who induced tauK18 
aggregation before this threshold were considered as “positive”, whereas the other 
samples were considered as “negative”. By applying this threshold, we were able to identify 
as positive 4/5 primary tauopathies (3/3 FTD and 1/1 CBD) and 8/8 AD samples. Only one 
out of four HC samples (EXO#2, dark olive green line) was considered positive. Conversely, 
PSP sample was considered negative.  
Figure 4.20. RT-QuIC analysis of urinary exosomes collected from patients with tauopathies and healthy 
controls. 
A) tauK18 aggregation was efficiently triggered by exosomes isolated from patients with tauopathies and 
by some HC samples. A threshold was settled at 10’000 AU and 10 hours from the beginning of the 
reaction to distinguish samples characterized by higher (considered as “positive”) and lower tauK18 
seeding activity (considered as “negative”). By applying this threshold (black dotted line), 4/5 primary 
tauopathies (3/3 FTD and 1/1 CBD) and 8/8 AD samples were considered positive, together with 1/4 HC 
sample (EXO#2, dark olive green line). PSP (orange line) and 3/4 HC samples (EXO#1, EXO#4 and 
EXO#3, olive green, dark green and light green lines) were considered negative. 
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When tauK18 aggregation kinetics triggered by exosomes isolated from primary and 
secondary tauopathies were analyzed together and were compared to HC samples, it was 
possible to confirm that secondary tauopathy (AD, dark red line) samples seeded tauK18 
aggregation with higher efficiency and reached an average higher fluorescence values if 
compared to primary tauopathies (FTD, CBD and PSP, light red line) and healthy controls 
(green line) (Fig. 4.21), thus allowing us to potentially discriminate between these 
conditions. Additional studies with a higher number of samples are required to validate the 
specificity and sensitivity of our tauK18 RT-QuIC assay, however, this preliminary 
experiment showed that urinary exosomes collected from patients with tauopathies might 
possess tau seeding activity in vitro. 
Figure 4.21 RT-QuIC analysis of urinary exosomes collected from patients with tauopathies and healthy 
controls. 
Comparison between tauK18 aggregation kinetics seeded by primary (FTD, CBD, and PSP, light red line) 
and secondary (AD, dark red line) tauopathies and healthy controls (green line), showing that AD urine 
exosomes possessed the highest tauK18 seeding activity in RT-QuIC. 
 
4.7. RT-QuIC analysis of CSF collected from patients with Alzheimer’s disease 
To further evaluate the potential applicability of our tauK18 RT-QuIC assay, we decide to 
analyze CSF samples collected from AD patients and to compare their seeding activity with 
CSF collected from Non-demented patients (NDP).  
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In a preliminary experiment, we compared tauK18 seeding ability of 3 AD CSF to 3 NDP 
CSF samples in RT-QuIC. Results (Fig. 4.22) revealed the ability of 2 out of 3 AD CSF (CSF#1 
and CSF#2, light red and red lines) to efficiently accelerate tauK18 aggregation. No 
increase in fluorescence was observed after the addition of CSF collected from non-
demented patients. 
Figure 4.22 RT-QuIC analysis of CSF collected from patients with AD and non-demented patients. 
RT-QuIC preliminary analysis of CSF samples showed that tauK18 aggregation was triggered by 2 out of 
3 CSF samples from patients with AD (CSF#1 and CSF#2, light red and red lines). No increase in 
fluorescence was observed after the addition of CSF collected from non-demented patients. 
 
Given that CSF seemed to have an inhibitory effect on tauK18 aggregation, we performed 
another experiment by adding a lower volume of CSF and we analyzed 8 AD and 8 NDP 
CSF samples.  
Results showed that, with this new experimental setting, a greater number of CSF samples 
triggered tauK18 aggregation (Fig. 4.23). In particular, all AD CSF samples displayed tauK18 
seeding activity, together with 7 out of 8 NDP CSF samples. Similarly to what we have done 
in the analysis of urinary exosomes, we apply a threshold settled at 10’000 AU of 
fluorescence intensity and at 10 hours from the beginning of reaction, to distinguish 
samples characterized by a higher seeding activity from those who triggered tauK18 
aggregation with less efficiency (Fig. 4.23, black dotted lines). Samples who induced tauK18 
aggregation before this threshold were considered as “positive”, whereas the other 
samples were considered as “negative”. Thus, we identified as positive 7/8 AD CSF samples 
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and 5/8 NDP CSF samples. One AD CSF sample (CSF#6, pink line) was considered negative 
as it induced tauK18 aggregation after 20 hours from the beginning of the reaction. 
Similarly, 2 NDP CSF samples (CSF#3 and CSF#8, dark green and emerald green lines) 
displayed tauK18 seeding activity between 15 and 20 hours, thus they are considered as 
negative. One NDP sample (CSF#1, green line) did not induce tauK18 aggregation, 
showing to possess the same activity to that observed in the previous experiment (Fig. 
4.22).  
Figure 4.23 RT-QuIC analysis of CSF collected from patients with AD and non-demented patients. 
RT-QuIC analysis of CSF samples with this new experimental setting showed that all AD CSF samples and 
7 out of 8 NDP CSF samples displayed tauK18 seeding activity. Samples characterized by higher 
(considered as “positive”) and lower tauK18 seeding activity (considered as “negative”) were 
discriminated by applying a threshold settled at 10’000 AU of fluorescence intensity and at 10 hours from 
the beginning of reaction (black dotted line). 7/8 AD CSF samples were considered as positive and 5/8 
CSF samples were considered as negative. No increase in fluorescence was observed after the addition 
of one NDP CSF sample (CSF#1, green line). 
 
Similar results were also obtained when we analyzed aggregation kinetics of all AD CSF 
samples and we compared it to NDP samples (Fig. 4.24).  
Indeed, no differences in the average lag phases and fluorescence intensities have been 
observed among the two groups, thus indicating that with this experimental setting AD 
and NDP CSF samples displayed the same tauK18 seeding activity in RT-QuIC. 
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Figure 4.21 RT-QuIC analysis of CSF collected from patients with Alzheimer’s disease and non-demented 
patients. 
Comparison between tauK18 aggregation kinetics seeded by AD (dark red line) and non-demented 
patients (green line), showing that both groups displayed the same tauK18 seeding activity in RT-QuIC. 
 
4.8. Evaluation of cross-seeding activity of different amyloidogenic proteins 
on tauK18 aggregation in RT-QuIC 
When performing the analysis of peripheral tissues collected from patients with different 
forms of dementia, the discrete level of inaccuracy in the aforementioned clinical diagnosis 
might present an issue for the correct interpretation of RT-QuIC results. Thus, we tried to 
recapitulate in vitro the effect that other misfolded proteins commonly found in NDs might 
exert on tauK18 aggregation in RT-QuIC to evaluate if they are capable of cross-seeding 
activity in our assay.  
To this aim, we firstly generated aggregates of tauK19 (3R tau fragment), αS, Aβ1-40, Aβ1-42 
by inducing their self-assembly into PFFs in RT-QuIC, following specific experimental 
conditions for each protein previously settled in our laboratory. tauK18 PFFs were 
generated as previously described (Paragraph 4.1) and were used as control. The presence 
of fibrils was confirmed by TEM, as shown in Fig 4.22. Given that tauK18, tauK19, αS, Aβ1-40, 
and Aβ1-42 PFFs were generated starting from different protein concentrations, we diluted 
all PFFs sample in order to add the same amount of fibrils (estimated to be in the order of 
nanograms) in each reaction mix.  
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Figure 4.22 TEM images of tauK18, tauK19, tauK19, αS, Aβ1-40, and Aβ1-42 PFFs 
TEM analysis of final RT-QuIC products of self-assembly reactions showed the presence of fibrils in 
tauK18, tauK19, αS, Aβ1-40, and Aβ1-42 PFFs samples. 
 
As reported in Fig. 4.23, tauK18 aggregation was specifically accelerated only by tauK18 
PFFs homologous seeding (red line). The addition of Aβ1-40 and Aβ1-42 PFFs did not modify 
tauK18 aggregation, as its fibrillization kinetics in both samples (green and purple lines) 
was comparable to that of tauK18 self-assembly (black dotted line). Conversely, tauK19 
and αS PFFs delayed tauK18 aggregation, as no increase in fluorescence intensities was 
observed even after 40 hours from the beginning of the reaction (orange and blue lines). 
These results suggested that homologous seeding should be more efficient than 
heterologous one in our RT-QuIC assay under these experimental settings. 
Figure 4.22 RT-QuIC analysis of tauK18, tauK19, αS, Aβ1-40, and Aβ1-42 PFFs 
RT-QuIC analysis of the effect exerted by tauK19, αS, Aβ1-40 and Aβ1-42 PPFs on tauK18 aggregation 
showed the absence of cross-seeding activity from heterologous PFFs in our experimental setting. 
tauK18 PFFs were used as comparison and efficiently induced tauK18 aggregation, thus confirming that 
homologous seeding was more efficient than heterologous one.  
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To investigate whether the presence of other amyloidogenic proteins might have induced 
the formation of tauK18 fibrils with different morphologies, final tauK18 RT-QuIC reaction 
products were collected and analyzed by means of TEM and AFM. TEM and AFM images 
are shown in Fig. 4.23 and revealed morphologically different tauK18 fibrils in each sample. 
Interestingly, such differences were comparable between TEM and AFM analysis. Indeed, 
tauK18 self-assembly generated thin and unstructured fibrils, whereas tauK18 homologous 
seeding induced the formation of well-structured fibrils arranged in intricate tangles. Few 
disperse tauK18 fibrils were observed in samples containing tauK19, αS and Aβ1-42 PFFs. 
The addition of Aβ1-40 PFFs induced the formation of long tauK18 fibrils characterized by a 
circular morphology. These preliminary results suggested that the addition of different 
seeds, although not accelerating the aggregation of the substrate, might influence the 
morphology of tauK18 final RT-QuIC fibrils. 
 
Figure 4.23. TEM and AFM analysis of tauK18 final RT-QuIC products after the addition of tauK18, 
tauK19, tauK19, αS, Aβ1-40, and Aβ1-42 PFFs 
TEM and AFM analysis of final products of tauK18 self-assembly and reactions supplemented with 
different PFFs, showing that self-assembly reaction generated thin and unstructured fibrils, whereas 
tauK18 homologous seeding induced the formation of well-structured fibrils arranged in intricate tangles. 
Few disperse tauK18 fibrils were observed in samples containing tauK19, αS and Aβ1-42 PFFs. The addition 
of Aβ1-40 PFFs induced the formation of long tauK18 fibrils characterized by a circular morphology. 
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Given that we observed tauK18 seeding activity in RT-QuIC after the addition of OM 
samples collected from patients with a clinical diagnosis of synucleinopathies, we further 
investigated the effect exerted by different species of αS aggregates (oligomers, early-
fibrils, and late-fibrils) on tauK18 aggregation. 
Thus, we induced αS to self-assembly by means of RT-QuIC and we collected oligomers, 
early-fibrils, and late-fibrils at different time points of the aggregation kinetics, as depicted 
in Fig. 4.24A. The same species of tauK18 aggregates were also generated and used as 
controls (Fig. 4.23B). The presence of such species was confirmed by TEM (Fig. 4.23C and 
D) in both αS and tauK18 samples. Indeed, oligomers were observed as protein aggregates 
with different diameters and arranged in a linear fashion (Fig. 4.23C and D, light blue and 
orange arrows). Early-fibrils samples displayed the presence of short filaments (Fig. 4.23C 
and D, blue and red arrows), whereas late-fibrils were composed by clusters of long 
filaments (Fig. 4.23C and D, dark blue and dark red arrows). 
Figure 4.24. Generation of oligomers, early-fibrils, and late-fibrils of αS and tauK18 
A) αS self-assembly in RT-QuIC, showing the collection of oligomers (light blue circle), early-fibrils (blue 
circle) and late-fibrils (dark blue circle). B) tauK18 self-assembly in RT-QuIC, showing the collection of 
oligomers (orange circle), early-fibrils (red circle) and late-fibrils (dark red circle). C) TEM analysis of the 
species collected confirmed the presence of αS oligomers (light blue arrow), early-fibrils (blue arrow) and 
late-fibrils (dark blue arrow). D) TEM analysis of the species collected showed the presence of tauK18 
oligomers (orange arrow), early-fibrils (red arrow) and late-fibrils (dark red arrow). 
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Oligomers, early-fibrils, and late-fibrils were subsequently added to new tauK18 reaction 
mixes and their seeding ability was assessed in RT-QuIC. Conversely, all the misfolded αS 
species generated were able to interfere with tauK18 aggregation (Fig. 4.25), thus 
confirming results obtained with the previous experiment.  
Figure 4.23 RT-QuIC analysis of the effect exerted by αS oligomers, early-fibrils, and late-fibrils on tauK18 
aggregation. 
RT-QuIC seeding assay showed that all αS species tested were able to interfere with tauK18 aggregation, 
as no increase in fluorescence intensities was observed after the addition of αS oligomers (light blue line), 
early-fibrils (blue line) and late-fibrils (dark blue line), even after 60 hours from the beginning of the 
reaction. tauK18 late-fibrils (dark red line) triggered tauK18 aggregation almost instantly. tauK18 
oligomers (orange line) did not accelerate tauK18 aggregation, however, its kinetics reached higher 
fluorescence values if compared to self-assembly reaction (black dotted line).  
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Indeed, no increase in fluorescence intensities was observed after the addition of αS 
oligomers (light blue line), early-fibrils (blue line) and late-fibrils (dark blue line), even after 
50 hours from the beginning of the reaction.  
Interestingly, tauK18 late-fibrils (dark red line) showed to possess the highest seeding 
activity if compared to early-fibrils (red line), as they triggered tauK18 aggregation almost 
instantly. Oligomers (orange line) did not seem to accelerate tauK18 aggregation, although 
its kinetics reached higher fluorescence values at the plateau if compared to self-assembly 
reaction (black dotted line).  
To explore the possibility that different conformational variant of the same misfolded 
protein might display different seeding activities on tauK18 aggregation, we generated 
four different conformational variants of αS aggregates (αS PFFs#1, PFFs#2, PFFs#3 and 
PFFs#4) by inducing its self-assembly in RT-QuIC using different aggregation buffers 
characterized by specific salts composition. The presence of misfolded αS characterized by 
different conformations was assessed by structural (Fig. 4.24A) and biochemical studies 
(Fig. 4.24B).  
 
Figure 4.24 Structural and biochemical analysis of αS PFFs#1, PFFs#2, PFFs#3 and PFFs#4 
A) TEM analysis αS PFFs generated by the use of different aggregation buffers showed the presence of 
straight fibrils with no (PFFs#1) or a very little amount of cross-overs (PFFs#2). PFFs#3 and PFFs#4 
samples displayed the presence of short and long twisted fibrils, respectively. Some oligomers were also 
observed in PFFs#3 and PFFs#4 samples, but not in PFFs#1 and PFFs#2. B) Silver staining of PK-treated 
PFFs revealed different profiles of PK-resistance: misfolded αS in PFFs#1 was partially resistant to 
proteolytic digestion (band at 14 kDa), whereas digested monomers led to the formation of 2 fragments 
with a MW in the range comprised between 12 and 10 kDa; in PFFs#2, misfolded αS was almost 
completely digested  and were cleaved producing a main fragment of approximately 10 kDa and other 
small fragments of 6-3 kDa; misfolded αS in PFFs#3 and #4 showed to possess the higher PK-resistance 
as intense bands were present at 14 kDa, however, their partial digestion produced fragments with a 
MW ranging from 12 and 3 kDa, and characterized by bands with different intensities. 
A B 
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TEM analysis of αS PFFs#1 and #2 showed that they were composed of straight fibrils with 
no (PFFs#1) or some cross-overs (PFFs#2). PFFs#3 and PFFs#4 samples displayed the 
presence of short and long twisted fibrils, respectively, together with some oligomers.  
Proteolytic digestion of αS PFFs samples showed that misfolded αS was characterized by 
different levels of resistance to PK-digestion in each PFFs (Fig. 4.24B). In particular, 
misfolded αS in PFFs#1 was partially resistant to such treatment, thus a band 
corresponding to αS monomers was still visible at 14 kDa. However, some monomers were 
digested and led to the formation of 2 fragments with a MW of 12 and 10 kDa. In PFFs#2, 
misfolded αS was almost completely digested by PK (a very faint band was visible at 14 
kDa) and its cleavage produced a main fragment of approximately 10 kDa, together with 
other small fragments of 6-3 kDa, which might represent the portion of the protein cleaved 
by PK. Misfolded αS in PFFs#3 and #4 showed to possess the higher PK-resistance as 
intense bands were present at 14 kDa. However, a partial digestion occurred and produced 
fragments with a MW ranging from 12 and 3 kDa. Interestingly, in PFFs#4 the band at 10 
kDa was more intense than in PFFs#3, thus suggesting that in this sample the 
conformation acquired by misfolded αS have influenced the proteolytic cleavage which 
was more efficient in generating this fragment in respect to the others.  
Figure 4.25 RT-QuIC analysis of αS PFFs#1, PFFs#2, PFFs#3 and PFFs#4. 
RT-QuIC analysis of different αS PFFs displayed distinct seeding abilities on tauK18 aggregation. PFFs#3 
(red line) and #4 (purple line) were able to trigger tauK18 aggregation, whereas PFFs#1 (blue line) 
seemed to interfere with the aggregation of the substrate. tauK18 aggregation was not influenced by the 
presence of PFFs#2 (green line), as its kinetics was comparable to tauK18 self-assembly (black dotted 
line). 
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When αS PFFs#1, #2, #3 and #4 were added to new reaction mixes, they displayed 
different seeding abilities on tauK18 aggregation. Indeed, tauK18 aggregation kinetics was 
accelerated by αS PFFs#3 and PFFs#4, whereas PFFs#1 delayed the aggregation of the 
substrate. Interestingly, tauK18 aggregation in the presence of PFFs#2 was comparable to 
that of tauK18 self-assembly, thus suggesting that such strain was not able to influence 
tauK18 aggregation. Taken together, these studies suggested that different conformational 
variants of αS may differentially influence the aggregation of tauK18 in RT-QuIC, thus 
representing an issue for our RT-QuIC assay. 
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CHAPTER V 
DISCUSSION 
 
NDs are conditions associated with the intracerebral accumulation of abnormally 
folded proteins, which are considered disease-specific biomarkers (DSB). Definitive 
diagnosis of NDs relies on neuropathological examination of brain collected at autopsy 
with the aim of detecting and identifying DSB. However, recent findings suggest that DSB 
might circulate in peripheral tissues at concentrations that are under the detection limits of 
the classical diagnostic techniques (e.g. ELISA, Western blot). Therefore, clinical diagnosis 
of NDs is very challenging, especially in the early stages of the disease. This is mainly due 
to the fact that some clinical manifestations might overlap between different conditions. 
Moreover, the lack of tools useful for detecting peripheral DSB limits the diagnostic 
accuracy of such diseases.  
The advent of cell-free amplification systems such as the PMCA and RT-QuIC 
stimulated unprecedented advancement in terms of developing robust diagnostic tests for 
many NDs, identifying novel therapeutic strategies and disinfection procedures. Originally 
developed and successfully applied in the field of prion disease diagnosis, both techniques 
are currently being optimized for the analysis of the aggregation process of other proteins, 
including A, tau and -synuclein (S). In particular, several RT-QuIC studies have been 
carried on CSF samples that are often collected from patients with a clinical diagnosis of 
NDs. However, our research group was aimed at optimizing this technique for the analysis 
of olfactory mucosa (OM) and urine samples which are less invasive to be collected than 
CSF. In this regard, since 2013, our research group has been collecting olfactory mucosa 
samples from patients with NDs and now owns more than 300 samples of OM ready to be 
subjected to RT-QuIC and PMCA analyses aimed at detecting DSB.  
We have recently demonstrated a successful application of the RT-QuIC technology 
in detecting S seeding activity in OM samples collected from patients Parkinson’s disease 
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(PD) and Multiple system atrophy (MSA) [251]. Interestingly, final RT-QuIC products 
acquired biochemical and structural features that were disease-dependent. PD and MSA 
are parkinsonian syndromes whose diagnosis is challenged due to their overlapping 
symptoms with other atypical parkinsonisms, such as Progressive supranuclear palsy (PSP) 
and Corticobasal degeneration (CBD), which are instead characterized by the deposition of 
tau. 
For this reason, my PhD thesis aimed at optimizing an RT-QuIC assay where human 
recombinant tau (the 4R fragment, named tauK18) was used as reaction substrate. We 
decided to use this fragment for different reasons. First of all, preliminary experiments 
showed that the aggregation properties and kinetics of tauK18 were much more 
reproducible if compared to that obtained with the use of the full-length 4R tau. Secondly, 
we decided to focus our study on the analysis of primary tauopathies mainly characterized 
by the accumulation of 4R tau (CBD and PSP). We also included the analysis of secondary 
tauopathies, such as Alzheimer’s disease (AD) patients, because of the presence of both 4R 
and 3R tau. Given that misfolded 4R tau in patients with tauopathies showed to be 
conformationally different, the tauK18 fragment could represent an ideal RT-QuIC reaction 
substrate for the amplification of different conformational variants of 4R tau as it contains 
the aggregation-prone domain of the protein identified as the core of 4R tau fibrils.  
Therefore, we have hypothesized that our RT-QuIC technology could have been 
useful for detecting seeding activity of 4R tau present in peripheral tissues (OM and urine) 
of patients with PSP and CBD with high efficiency. Data from the literature have shown that 
3R full-length tau is able to hamper the aggregation of 4R tau [260], thus we were 
expecting a lower seeding activity in samples collected from Alzheimer’s disease patients. 
First, we performed several experiments to find the optimal conditions for tauK18 
aggregation in RT-QuIC. Subsequently, we focused on seeding studies. Our results have 
demonstrated that the technique is very sensitive in detecting seeding activity of extremely 
low levels (attograms) of tauK18 preformed fibrils (PFFs) artificially produced in vitro.   
Given the high sensitivity of the assay, we decide to assess if tauK18 aggregation 
might be similarly accelerated by pathological misfolded tau present in brains of patients 
 112 
 
with primary and secondary tauopathies. Interestingly, our RT-QuIC assay was able to 
detect tau seeding activity in BH of patients with primary and secondary tauopathies, 
whereas HC BH sample also slightly induced tauK18 aggregation. Its fluorescence values, 
however, reached significantly lower levels if compared to other BH samples. Its mild 
seeding ability might be due to the presence of BH components able to unspecifically 
trigger tauK18 aggregation. In our second hypothesis, it might be due to the presence of 
misfolded proteins, as they are increasingly found in cognitively normal subjects [261-263], 
potentially capable of cross-seeding activity.  
The finding that DLB BH delayed tauK18 aggregation was quite surprising, as several 
in vitro and in vivo observations reported that misfolded S might act as a strong inductor 
of tau aggregation [264]. Even if S did not cross-seed tauK18 in our assay, we were not 
expecting such an inhibitory effect. It is possible that also in this case BH components 
influenced tauK18 RT-QuIC assay. Indeed, it is important to mention that endogenous 
polar brain lipids were shown to inhibit prion amplification in RT-QuIC, therefore 
representing a potential issue for our assay [265]. Or, the presence of aggregated S in the 
brain of a patient with DLB may have interfered with tauK18 self-aggregation.  
Interestingly, the use of AD brain homogenate efficiently promoted tauK18 
aggregation. This effect might be associated with a higher seeding efficiency of 4R if 
compared to 3R aggregates, which have been shown to inhibit 4R tau aggregation. It is 
also possible that other factors concurred in inducing tauK18 aggregation. For instance, in 
the amyloid cascade hypothesis, A can trigger tau aggregation [266]. In this regard, it may 
be possible that, although the presence of 3R tau might have exerted an inhibitory effect 
on tauK18 aggregation, the presence of 4R tau and A might have significantly promoted 
the aggregation propensities of tauK18.  
When we tested dilutions of brain samples, our assay demonstrated a lower 
sensitivity and specificity in detecting pathological tau from brain samples if compared to 
tauK18 PFFs seeding assay. However, although we estimated that our tauK18 RT-QuIC 
assay is able to detect tau seeding activity exerted by attograms of tauK18 PFFs, it is 
conceivable that this ability is strictly related to the fact that these aggregates were 
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generated in vitro starting from the same protein fragment (tauK18) and without any other 
material that can interfere with the assay.  
Therefore, even if the sensitivity of tauK18 RT-QuIC assay in detecting BH 
pathological tau was lower than tauK18 PFFs, we decided to analyze tau seeding activity in 
peripheral tissues and body fluids of patients with a clinical diagnosis of CBD, PSP, FTDP-
17, and AD, as these samples might contain less amount of molecules able to alter tauK18 
aggregation in RT-QuIC. We initially focused our attention on olfactory mucosa (OM) 
samples as they are easy to collect with a non-invasive procedure and they have been 
shown to contain olfactory neurons likely containing misfolded proteins in patients with 
NDs. Indeed, neuropathological evaluation of olfactory epithelium collected at autopsy 
from patients with AD showed the presence of Aβ plaques and PHF-tau pathology [267]. 
To this aim, we analyzed OM samples collected from several primary and secondary 
tauopathies and we compared their seeding abilities with OM collected from 
synucleinopathies and Multiple sclerosis (MS). We were able to observe tau seeding 
activity in some OM samples collected from patients with PSP and CBD, while those 
collected from FTDP-17 and AD patients did not. The lack of seeding abilities of FTDP-17 
and AD OM samples might be explained by the presence of molecules (e.g. lipids) able to 
inhibit tau18 aggregation. Indeed, OM is composed of a mucous layer rich in lipids that 
cover the surface of receptors at the epithelium surface and assist in transporting odorant 
molecules to the olfactory receptors [268]. In support of this hypothesis, FTIR analysis of 
final tauK18 RT-QuIC products of OM seeding incidentally showed the presence of 
absorbance peaks in the region around 1740 cm-1 which indicated the presence of lipids in 
those samples. Interestingly, AD OM sample displayed a very high peak in this region, thus 
suggesting a potential higher content of lipids if compared to other OM samples. 
Numerous efforts have been made to exclude such factors from our assay, however, by 
diluting OM samples it is possible that also seeding-competent tau was diluted, altering 
the sensitivity of our tauK18 RT-QuIC assay.  
Given that OM samples from atypical parkinsonisms (PSP, CBD, and PD) have shown 
a greater seeding activity in our experimental conditions if compared to AD and FTDP-17 
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samples, we have decided to focus our attention on this group of diseases with the aim at 
recognizing parkinsonian syndromes associated with tau pathology and to distinguish 
them from those associated to αS accumulation. Surprisingly, some OM samples from 
patients with PD, DLB, and MSA triggered tauK18 aggregation in RT-QuIC. Given that DLB 
BH sample displayed an inhibitory effect, we hypothesized that different strains of αS 
might differentially influence tau aggregation in our assay.   
We tried to recapitulate such condition by generating different conformational 
variants of αS PFFs and by evaluating their effect of tauK18 aggregation. We noticed that 
some PFFs triggered tauK18 aggregation, whereas one PFFs delayed its aggregation, thus 
indicating that the conformation acquired by αS aggregates might play a role in 
influencing their cross-seeding abilities in our assay. On the other hand, we also 
hypothesized the presence of misfolded tau in patients with PD, DLB, and MSA. Indeed, an 
increasing number of studies are reporting the presence of concomitants αS and tau 
pathologies in several NDs, often associated with a faster disease progression and the 
worst prognosis [85, 269]. Moreover, PARK8 subtype of genetic PD has been shown at 
neuropathological examination to contain also tau deposits with or without forming 
neurofibrillary tangles [270]. This finding might explain seeding activity of gPD (PARK8) OM 
in our tauK18 RT-QuIC assay. 
Finally, the discrete level of inaccuracy in the aforementioned clinical diagnosis 
might present an issue for the correct interpretation of RT-QuIC results. For this reason, we 
assessed the cross-seeding abilities of other amyloidogenic proteins commonly found in 
other NDs. Thus, we tested the effect that αS, tauK19 (3R-tau), Aβ1-40 and Aβ1-42 PFFs might 
exert on tauK18 aggregation. Initially, the substrate showed to be specifically accelerated 
only by tauK18 PFFs. However, this observation is strictly related to the specific 
experimental conditions used in our assay and to the fact that such PFFs were generated in 
vitro, thus not resembling pathological misfolded proteins found in vivo. Indeed, when we 
generated different conformational variants of αS, some of them showed to accelerate 
tauK18 aggregation, whereas one PFFs seemed to interfere with tauK18 aggregation. Thus, 
we hypothesized that DLB brain might contain one strain of αS not capable of tauK18 
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seeding activity, whereas DLB OM can contain αS aggregates able to induce tauK18 
aggregation in RT-QuIC. In the field of prion diseases, it has been shown that two or more 
prion strains can co-exist in sporadic cases of CJD [271{Puoti, 1999 #7503, 272]. Moreover, 
in PDD cases Lewy bodies in the substantia nigra showed biochemical dissimilarities from 
LBs in neocortical areas of the same patients, thus suggesting that different misfolded αS 
conformations might accumulate in different cerebral areas [35]. 
Given the possibility that different seeds might have induced tauK18 aggregation, 
we decided to couple RT-QuIC technique with biochemical and structural evaluations of 
final reaction products to assess if they might have acquired different conformations. In 
particular, final tauK18 RT-QuIC products of reactions seeded by PSP, CBD and AD OM 
samples were subjected to preliminary structural studies by means of TEM, AFM and FTIR 
analysis. Thanks to these assessments we have observed that final aggregates were 
characterized by different structural features when seeded by CBD, PSP and PD OM. 
Similarly, it was possible to identify morphological differences in tauK18 seeded by 
different PFFs. If this will be confirmed, structural and biochemical evaluations of tauK18 
final RT-QuIC products may be helpful for identifying different seeding-competent tau 
strains and help for the stratification of patients in the early stages of the disease. This, in 
turn, will lead to lay the foundation for a precision medicine which is directed against 
individual pathological processes. 
The low specificity and sensitivity of our assay in detecting tau seeding activity in 
OM from patients with tauopathies moved us to the analysis of body fluids, such as urine. 
Given that urine contains a lot of metabolic products, we decided to isolate exosomes as 
they have been shown to potentially contain protein aggregates and to participate in 
misfolding progression in patients with NDs. RT-QuIC analysis of urinary exosomes showed 
improved results: indeed, urine exosomes collected from patients with Alzheimer’s disease 
showed higher tauK18 seeding activity if compared to CBD, PSP and control samples. By 
applying a threshold to distinguish samples characterized by a higher seeding activity 
(considered as “positive”) from those who triggered tauK18 aggregation with less 
efficiency (considered as “negative), we were able to identify as positive 4/5 primary 
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tauopathies (3/3 FTD and 1/1 CBD) and 8/8 AD samples. Only one out of four HC samples 
was considered positive. Additional studies with a higher number of samples are required 
to validate such results, however, these findings suggested that exosomes isolated from 
body fluids may represent a suitable source of misfolded protein circulating in the 
periphery. Given that tau accumulates inside the cell in brain of patients with tauopathies, 
exosomes might actively contribute to tau pathology spreading in body fluids. 
To further evaluate the potential applicability of our tauK18 RT-QuIC assay, we 
decide to analyze CSF samples collected from AD patients. We found that tauK18 
aggregation was accelerated from all the AD CSF tested, but also from some NDP CSF 
samples. Similarly to what we hypothesized in the previous analysis, CSF might contain 
proteins or molecules able to promote tauK18 aggregation. Additional studies with a 
higher number of samples are required to further optimize RT-QuIC analysis of CSF 
collected from patients with AD and to apply this technology to the analysis of CSF 
samples from other tauopathies. 
These studies represent a fundamental step forward in the field of NDs since it 
demonstrates that CSF, olfactory mucosa and urine collected from patients at different 
stages of disease might be exploited for formulating a definitive diagnosis of many NDs 
without the need of autoptic confirmatory tests.  Moreover, these results could be 
achieved by simple analyses of easily collectable peripheral tissues without the use of 
invasive procedures. As consequence, it will (1) limit the need of other costly and time 
consuming clinical, laboratory or instrumental tests, (2) reduce the number of specialist 
consultations, (3) reduce the length of waiting lists to access specialist clinics while (4) 
improving selection of patients to be enrolled in clinical trials. The possibility to collect 
samples at different stages of the disease will enable the monitoring of the effects that 
specific drugs exert on DSB concentration or in modifying their biochemical and structural 
features. In addition, since RT-QuIC mimics the same process of protein misfolding which 
occurs in vivo, it might be used to study how therapeutic compounds block the molecular 
events which lead to dementia, thus focusing the analysis on molecular rather than 
symptomatic aspects. 
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